CA2276548C - Improved methods for the preparation of endotoxin-binding proteins - Google Patents
Improved methods for the preparation of endotoxin-binding proteins Download PDFInfo
- Publication number
- CA2276548C CA2276548C CA002276548A CA2276548A CA2276548C CA 2276548 C CA2276548 C CA 2276548C CA 002276548 A CA002276548 A CA 002276548A CA 2276548 A CA2276548 A CA 2276548A CA 2276548 C CA2276548 C CA 2276548C
- Authority
- CA
- Canada
- Prior art keywords
- leu
- protein
- ser
- val
- sepharose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 108010072542 endotoxin binding proteins Proteins 0.000 title abstract description 14
- 238000002360 preparation method Methods 0.000 title description 6
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 claims abstract description 7
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 claims abstract description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 24
- 238000002955 isolation Methods 0.000 abstract description 16
- 239000006143 cell culture medium Substances 0.000 abstract description 12
- 238000005341 cation exchange Methods 0.000 abstract description 8
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 abstract description 4
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 description 58
- 108090000623 proteins and genes Proteins 0.000 description 58
- 235000018102 proteins Nutrition 0.000 description 56
- 229920002684 Sepharose Polymers 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 40
- 239000008351 acetate buffer Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 23
- 239000002609 medium Substances 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 102100035131 Lipopolysaccharide-binding protein Human genes 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 description 9
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 4
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- JYOAXOMPIXKMKK-YUMQZZPRSA-N Leu-Gln Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCC(N)=O JYOAXOMPIXKMKK-YUMQZZPRSA-N 0.000 description 3
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 3
- LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- UJTZHGHXJKIAOS-WHFBIAKZSA-N Ser-Gln Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O UJTZHGHXJKIAOS-WHFBIAKZSA-N 0.000 description 3
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 3
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 3
- 108010070741 Tachypleus tridentatus tachyplesin peptide Proteins 0.000 description 3
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 3
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 3
- XXDVDTMEVBYRPK-XPUUQOCRSA-N Val-Gln Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O XXDVDTMEVBYRPK-XPUUQOCRSA-N 0.000 description 3
- RLVTVHSDKHBFQP-ULQDDVLXSA-N Val-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=C(O)C=C1 RLVTVHSDKHBFQP-ULQDDVLXSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 108010091798 leucylleucine Proteins 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 108010079317 prolyl-tyrosine Proteins 0.000 description 3
- 108010053725 prolylvaline Proteins 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- ZJQFYZCNRTZAIM-PMXBASNASA-N tachyplesin Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@H](C(N[C@H]2CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](N)CCCCN)CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZJQFYZCNRTZAIM-PMXBASNASA-N 0.000 description 3
- 108010061238 threonyl-glycine Proteins 0.000 description 3
- 108010009962 valyltyrosine Proteins 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- YHKANGMVQWRMAP-DCAQKATOSA-N Ala-Leu-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YHKANGMVQWRMAP-DCAQKATOSA-N 0.000 description 2
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 2
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 2
- GNYUVVJYGJFKHN-RVMXOQNASA-N Arg-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N GNYUVVJYGJFKHN-RVMXOQNASA-N 0.000 description 2
- WYBVBIHNJWOLCJ-IUCAKERBSA-N Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N WYBVBIHNJWOLCJ-IUCAKERBSA-N 0.000 description 2
- MQLZLIYPFDIDMZ-HAFWLYHUSA-N Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O MQLZLIYPFDIDMZ-HAFWLYHUSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 2
- XMBSYZWANAQXEV-QWRGUYRKSA-N Glu-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-QWRGUYRKSA-N 0.000 description 2
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 2
- KGVHCTWYMPWEGN-FSPLSTOPSA-N Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CN KGVHCTWYMPWEGN-FSPLSTOPSA-N 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- IXHQLZIWBCQBLQ-STQMWFEESA-N Gly-Pro-Phe Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IXHQLZIWBCQBLQ-STQMWFEESA-N 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 2
- VLDVBZICYBVQHB-IUCAKERBSA-N His-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CN=CN1 VLDVBZICYBVQHB-IUCAKERBSA-N 0.000 description 2
- BBIXOODYWPFNDT-CIUDSAMLSA-N Ile-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O BBIXOODYWPFNDT-CIUDSAMLSA-N 0.000 description 2
- TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 2
- CQGSYZCULZMEDE-SRVKXCTJSA-N Leu-Gln-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CQGSYZCULZMEDE-SRVKXCTJSA-N 0.000 description 2
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 2
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 2
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 2
- CTVJSFRHUOSCQQ-DCAQKATOSA-N Met-Arg-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CTVJSFRHUOSCQQ-DCAQKATOSA-N 0.000 description 2
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 2
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 2
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 2
- AWJGUZSYVIVZGP-YUMQZZPRSA-N Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 AWJGUZSYVIVZGP-YUMQZZPRSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 2
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 description 2
- XCTHZFGSVQBHBW-IUCAKERBSA-N Val-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])C(C)C XCTHZFGSVQBHBW-IUCAKERBSA-N 0.000 description 2
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 2
- GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 description 2
- VEYJKJORLPYVLO-RYUDHWBXSA-N Val-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VEYJKJORLPYVLO-RYUDHWBXSA-N 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- ZVDPYSVOZFINEE-BQBZGAKWSA-N alpha-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O ZVDPYSVOZFINEE-BQBZGAKWSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010033706 glycylserine Proteins 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- -1 sulfopropyl Chemical group 0.000 description 2
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 2
- 108010036320 valylleucine Proteins 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710132383 66 kDa protein Proteins 0.000 description 1
- LJTZPXOCBZRFBH-CIUDSAMLSA-N Ala-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N LJTZPXOCBZRFBH-CIUDSAMLSA-N 0.000 description 1
- GJMNLCSOIHOLQZ-FXQIFTODSA-N Ala-Ala-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(O)=O GJMNLCSOIHOLQZ-FXQIFTODSA-N 0.000 description 1
- SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 description 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
- SKHCUBQVZJHOFM-NAKRPEOUSA-N Ala-Arg-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SKHCUBQVZJHOFM-NAKRPEOUSA-N 0.000 description 1
- XCVRVWZTXPCYJT-BIIVOSGPSA-N Ala-Asn-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N XCVRVWZTXPCYJT-BIIVOSGPSA-N 0.000 description 1
- IKKVASZHTMKJIR-ZKWXMUAHSA-N Ala-Asp-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IKKVASZHTMKJIR-ZKWXMUAHSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 1
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 1
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 1
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 1
- ZEBDYGZVMMKZNB-SRVKXCTJSA-N Arg-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCN=C(N)N)N ZEBDYGZVMMKZNB-SRVKXCTJSA-N 0.000 description 1
- UGZUVYDKAYNCII-ULQDDVLXSA-N Arg-Phe-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UGZUVYDKAYNCII-ULQDDVLXSA-N 0.000 description 1
- VUGWHBXPMAHEGZ-SRVKXCTJSA-N Arg-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N VUGWHBXPMAHEGZ-SRVKXCTJSA-N 0.000 description 1
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 1
- UPALZCBCKAMGIY-PEFMBERDSA-N Asn-Gln-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UPALZCBCKAMGIY-PEFMBERDSA-N 0.000 description 1
- QDXQWFBLUVTOFL-FXQIFTODSA-N Asn-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)N)N QDXQWFBLUVTOFL-FXQIFTODSA-N 0.000 description 1
- VCJCPARXDBEGNE-GUBZILKMSA-N Asn-Pro-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 VCJCPARXDBEGNE-GUBZILKMSA-N 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 description 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 1
- VWWAFGHMPWBKEP-GMOBBJLQSA-N Asp-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)N VWWAFGHMPWBKEP-GMOBBJLQSA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 1
- 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- BUXAPSQPMALTOY-WHFBIAKZSA-N Cys-Glu Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BUXAPSQPMALTOY-WHFBIAKZSA-N 0.000 description 1
- KABHAOSDMIYXTR-GUBZILKMSA-N Cys-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N KABHAOSDMIYXTR-GUBZILKMSA-N 0.000 description 1
- SDXQKJAWASHMIZ-CIUDSAMLSA-N Cys-Glu-Met Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O SDXQKJAWASHMIZ-CIUDSAMLSA-N 0.000 description 1
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000896693 Disa Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FAQVCWVVIYYWRR-WHFBIAKZSA-N Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 description 1
- KCJJFESQRXGTGC-BQBZGAKWSA-N Gln-Glu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O KCJJFESQRXGTGC-BQBZGAKWSA-N 0.000 description 1
- JEFZIKRIDLHOIF-BYPYZUCNSA-N Gln-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(O)=O JEFZIKRIDLHOIF-BYPYZUCNSA-N 0.000 description 1
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 1
- ITZWDGBYBPUZRG-KBIXCLLPSA-N Gln-Ile-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O ITZWDGBYBPUZRG-KBIXCLLPSA-N 0.000 description 1
- SHAUZYVSXAMYAZ-JYJNAYRXSA-N Gln-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N SHAUZYVSXAMYAZ-JYJNAYRXSA-N 0.000 description 1
- CLSDNFWKGFJIBZ-YUMQZZPRSA-N Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O CLSDNFWKGFJIBZ-YUMQZZPRSA-N 0.000 description 1
- SXGMGNZEHFORAV-IUCAKERBSA-N Gln-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXGMGNZEHFORAV-IUCAKERBSA-N 0.000 description 1
- NHMRJKKAVMENKJ-WDCWCFNPSA-N Gln-Thr-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NHMRJKKAVMENKJ-WDCWCFNPSA-N 0.000 description 1
- KHHDJQRWIFHXHS-NRPADANISA-N Gln-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N KHHDJQRWIFHXHS-NRPADANISA-N 0.000 description 1
- VOORMNJKNBGYGK-YUMQZZPRSA-N Glu-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N VOORMNJKNBGYGK-YUMQZZPRSA-N 0.000 description 1
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 1
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 1
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- LKOAAMXDJGEYMS-ZPFDUUQYSA-N Glu-Met-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LKOAAMXDJGEYMS-ZPFDUUQYSA-N 0.000 description 1
- RXESHTOTINOODU-JYJNAYRXSA-N Glu-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCC(=O)O)N RXESHTOTINOODU-JYJNAYRXSA-N 0.000 description 1
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 1
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 1
- VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 description 1
- JSIQVRIXMINMTA-ZDLURKLDSA-N Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O JSIQVRIXMINMTA-ZDLURKLDSA-N 0.000 description 1
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 1
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- XUORRGAFUQIMLC-STQMWFEESA-N Gly-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O XUORRGAFUQIMLC-STQMWFEESA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 description 1
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- TWTPDFFBLQEBOE-IUCAKERBSA-N Gly-Leu-Gln Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O TWTPDFFBLQEBOE-IUCAKERBSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- PFMUCCYYAAFKTH-YFKPBYRVSA-N Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CN PFMUCCYYAAFKTH-YFKPBYRVSA-N 0.000 description 1
- JBCLFWXMTIKCCB-VIFPVBQESA-N Gly-Phe Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-VIFPVBQESA-N 0.000 description 1
- YABRDIBSPZONIY-BQBZGAKWSA-N Gly-Ser-Met Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O YABRDIBSPZONIY-BQBZGAKWSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- SFOXOSKVTLDEDM-HOTGVXAUSA-N Gly-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CN)=CNC2=C1 SFOXOSKVTLDEDM-HOTGVXAUSA-N 0.000 description 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 1
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 1
- IDXZDKMBEXLFMB-HGNGGELXSA-N His-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 IDXZDKMBEXLFMB-HGNGGELXSA-N 0.000 description 1
- ORERHHPZDDEMSC-VGDYDELISA-N His-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N ORERHHPZDDEMSC-VGDYDELISA-N 0.000 description 1
- NBWATNYAUVSAEQ-ZEILLAHLSA-N His-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O NBWATNYAUVSAEQ-ZEILLAHLSA-N 0.000 description 1
- JATYGDHMDRAISQ-KKUMJFAQSA-N His-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O JATYGDHMDRAISQ-KKUMJFAQSA-N 0.000 description 1
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 1
- FVEWRQXNISSYFO-ZPFDUUQYSA-N Ile-Arg-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N FVEWRQXNISSYFO-ZPFDUUQYSA-N 0.000 description 1
- AZEYWPUCOYXFOE-CYDGBPFRSA-N Ile-Arg-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)O)N AZEYWPUCOYXFOE-CYDGBPFRSA-N 0.000 description 1
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 1
- DMZOUKXXHJQPTL-GRLWGSQLSA-N Ile-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N DMZOUKXXHJQPTL-GRLWGSQLSA-N 0.000 description 1
- LKACSKJPTFSBHR-MNXVOIDGSA-N Ile-Gln-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N LKACSKJPTFSBHR-MNXVOIDGSA-N 0.000 description 1
- KTGFOCFYOZQVRJ-ZKWXMUAHSA-N Ile-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O KTGFOCFYOZQVRJ-ZKWXMUAHSA-N 0.000 description 1
- KEKTTYCXKGBAAL-VGDYDELISA-N Ile-His-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N KEKTTYCXKGBAAL-VGDYDELISA-N 0.000 description 1
- APDIECQNNDGFPD-PYJNHQTQSA-N Ile-His-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N APDIECQNNDGFPD-PYJNHQTQSA-N 0.000 description 1
- XMYURPUVJSKTMC-KBIXCLLPSA-N Ile-Ser-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N XMYURPUVJSKTMC-KBIXCLLPSA-N 0.000 description 1
- ZLFNNVATRMCAKN-ZKWXMUAHSA-N Ile-Ser-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZLFNNVATRMCAKN-ZKWXMUAHSA-N 0.000 description 1
- HXIDVIFHRYRXLZ-NAKRPEOUSA-N Ile-Ser-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)O)N HXIDVIFHRYRXLZ-NAKRPEOUSA-N 0.000 description 1
- BCXBIONYYJCSDF-CIUDSAMLSA-N Ile-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O BCXBIONYYJCSDF-CIUDSAMLSA-N 0.000 description 1
- RQZFWBLDTBDEOF-RNJOBUHISA-N Ile-Val-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N RQZFWBLDTBDEOF-RNJOBUHISA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
- UILIPCLTHRPCRB-XUXIUFHCSA-N Leu-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N UILIPCLTHRPCRB-XUXIUFHCSA-N 0.000 description 1
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 1
- QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 description 1
- QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 1
- DPWGZWUMUUJQDT-IUCAKERBSA-N Leu-Gln-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O DPWGZWUMUUJQDT-IUCAKERBSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
- JRJLGNFWYFSJHB-HOCLYGCPSA-N Leu-Gly-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRJLGNFWYFSJHB-HOCLYGCPSA-N 0.000 description 1
- AZLASBBHHSLQDB-GUBZILKMSA-N Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(C)C AZLASBBHHSLQDB-GUBZILKMSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- VVQJGYPTIYOFBR-IHRRRGAJSA-N Leu-Lys-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)O)N VVQJGYPTIYOFBR-IHRRRGAJSA-N 0.000 description 1
- INCJJHQRZGQLFC-KBPBESRZSA-N Leu-Phe-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O INCJJHQRZGQLFC-KBPBESRZSA-N 0.000 description 1
- KTOIECMYZZGVSI-BZSNNMDCSA-N Leu-Phe-His Chemical compound C([C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 KTOIECMYZZGVSI-BZSNNMDCSA-N 0.000 description 1
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
- RRVCZCNFXIFGRA-DCAQKATOSA-N Leu-Pro-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RRVCZCNFXIFGRA-DCAQKATOSA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- MVHXGBZUJLWZOH-BJDJZHNGSA-N Leu-Ser-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MVHXGBZUJLWZOH-BJDJZHNGSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- ODRREERHVHMIPT-OEAJRASXSA-N Leu-Thr-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ODRREERHVHMIPT-OEAJRASXSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- MDSUKZSLOATHMH-IUCAKERBSA-N Leu-Val Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C([O-])=O MDSUKZSLOATHMH-IUCAKERBSA-N 0.000 description 1
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- AEIIJFBQVGYVEV-YESZJQIVSA-N Lys-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCCN)N)C(=O)O AEIIJFBQVGYVEV-YESZJQIVSA-N 0.000 description 1
- YUTZYVTZDVZBJJ-IHPCNDPISA-N Lys-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 YUTZYVTZDVZBJJ-IHPCNDPISA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- LXCSZPUQKMTXNW-BQBZGAKWSA-N Met-Ser-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O LXCSZPUQKMTXNW-BQBZGAKWSA-N 0.000 description 1
- QAVZUKIPOMBLMC-AVGNSLFASA-N Met-Val-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C QAVZUKIPOMBLMC-AVGNSLFASA-N 0.000 description 1
- VYDLZDRMOFYOGV-TUAOUCFPSA-N Met-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N VYDLZDRMOFYOGV-TUAOUCFPSA-N 0.000 description 1
- MDSUKZSLOATHMH-UHFFFAOYSA-N N-L-leucyl-L-valine Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(O)=O MDSUKZSLOATHMH-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- SEPNOAFMZLLCEW-UBHSHLNASA-N Phe-Ala-Val Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O SEPNOAFMZLLCEW-UBHSHLNASA-N 0.000 description 1
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
- HTKNPQZCMLBOTQ-XVSYOHENSA-N Phe-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N)O HTKNPQZCMLBOTQ-XVSYOHENSA-N 0.000 description 1
- KLAONOISLHWJEE-QWRGUYRKSA-N Phe-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KLAONOISLHWJEE-QWRGUYRKSA-N 0.000 description 1
- KAGCQPSEVAETCA-JYJNAYRXSA-N Phe-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N KAGCQPSEVAETCA-JYJNAYRXSA-N 0.000 description 1
- WYPVCIACUMJRIB-JYJNAYRXSA-N Phe-Gln-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N WYPVCIACUMJRIB-JYJNAYRXSA-N 0.000 description 1
- QPVFUAUFEBPIPT-CDMKHQONSA-N Phe-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QPVFUAUFEBPIPT-CDMKHQONSA-N 0.000 description 1
- KZRQONDKKJCAOL-DKIMLUQUSA-N Phe-Leu-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KZRQONDKKJCAOL-DKIMLUQUSA-N 0.000 description 1
- OSBADCBXAMSPQD-YESZJQIVSA-N Phe-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N OSBADCBXAMSPQD-YESZJQIVSA-N 0.000 description 1
- GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 description 1
- JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 1
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 1
- JXQVYPWVGUOIDV-MXAVVETBSA-N Phe-Ser-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JXQVYPWVGUOIDV-MXAVVETBSA-N 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 1
- HXOLCSYHGRNXJJ-IHRRRGAJSA-N Pro-Asp-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HXOLCSYHGRNXJJ-IHRRRGAJSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- IWIANZLCJVYEFX-RYUDHWBXSA-N Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 IWIANZLCJVYEFX-RYUDHWBXSA-N 0.000 description 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
- SVXXJYJCRNKDDE-AVGNSLFASA-N Pro-Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CN=CN1 SVXXJYJCRNKDDE-AVGNSLFASA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 description 1
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
- AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
- RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 1
- OIDKVWTWGDWMHY-RYUDHWBXSA-N Pro-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 OIDKVWTWGDWMHY-RYUDHWBXSA-N 0.000 description 1
- DYJTXTCEXMCPBF-UFYCRDLUSA-N Pro-Tyr-Phe Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O DYJTXTCEXMCPBF-UFYCRDLUSA-N 0.000 description 1
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 1
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- KYKKKSWGEPFUMR-NAKRPEOUSA-N Ser-Arg-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KYKKKSWGEPFUMR-NAKRPEOUSA-N 0.000 description 1
- YMEXHZTVKDAKIY-GHCJXIJMSA-N Ser-Asn-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)C(O)=O YMEXHZTVKDAKIY-GHCJXIJMSA-N 0.000 description 1
- VBKBDLMWICBSCY-IMJSIDKUSA-N Ser-Asp Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O VBKBDLMWICBSCY-IMJSIDKUSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 description 1
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 1
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 1
- MUARUIBTKQJKFY-WHFBIAKZSA-N Ser-Gly-Asp Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MUARUIBTKQJKFY-WHFBIAKZSA-N 0.000 description 1
- BXLYSRPHVMCOPS-ACZMJKKPSA-N Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO BXLYSRPHVMCOPS-ACZMJKKPSA-N 0.000 description 1
- SBMNPABNWKXNBJ-BQBZGAKWSA-N Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CO SBMNPABNWKXNBJ-BQBZGAKWSA-N 0.000 description 1
- WGDYNRCOQRERLZ-KKUMJFAQSA-N Ser-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N WGDYNRCOQRERLZ-KKUMJFAQSA-N 0.000 description 1
- KJKQUQXDEKMPDK-FXQIFTODSA-N Ser-Met-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O KJKQUQXDEKMPDK-FXQIFTODSA-N 0.000 description 1
- XVWDJUROVRQKAE-KKUMJFAQSA-N Ser-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 XVWDJUROVRQKAE-KKUMJFAQSA-N 0.000 description 1
- RRVFEDGUXSYWOW-BZSNNMDCSA-N Ser-Phe-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RRVFEDGUXSYWOW-BZSNNMDCSA-N 0.000 description 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- VFWQQZMRKFOGLE-ZLUOBGJFSA-N Ser-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O VFWQQZMRKFOGLE-ZLUOBGJFSA-N 0.000 description 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 1
- YKRQRPFODDJQTC-CSMHCCOUSA-N Thr-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN YKRQRPFODDJQTC-CSMHCCOUSA-N 0.000 description 1
- UUSQVWOVUYMLJA-PPCPHDFISA-N Thr-Lys-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UUSQVWOVUYMLJA-PPCPHDFISA-N 0.000 description 1
- QNCFWHZVRNXAKW-OEAJRASXSA-N Thr-Lys-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QNCFWHZVRNXAKW-OEAJRASXSA-N 0.000 description 1
- IQHUITKNHOKGFC-MIMYLULJSA-N Thr-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IQHUITKNHOKGFC-MIMYLULJSA-N 0.000 description 1
- QOLYAJSZHIJCTO-VQVTYTSYSA-N Thr-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O QOLYAJSZHIJCTO-VQVTYTSYSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- UQCNIMDPYICBTR-KYNKHSRBSA-N Thr-Thr-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UQCNIMDPYICBTR-KYNKHSRBSA-N 0.000 description 1
- WKCFCVBOFKEVKY-HSCHXYMDSA-N Trp-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WKCFCVBOFKEVKY-HSCHXYMDSA-N 0.000 description 1
- 241000287433 Turdus Species 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- UBAQSAUDKMIEQZ-QWRGUYRKSA-N Tyr-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UBAQSAUDKMIEQZ-QWRGUYRKSA-N 0.000 description 1
- HDSKHCBAVVWPCQ-FHWLQOOXSA-N Tyr-Glu-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HDSKHCBAVVWPCQ-FHWLQOOXSA-N 0.000 description 1
- KCPFDGNYAMKZQP-KBPBESRZSA-N Tyr-Gly-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O KCPFDGNYAMKZQP-KBPBESRZSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
- CDBXVDXSLPLFMD-BPNCWPANSA-N Tyr-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDBXVDXSLPLFMD-BPNCWPANSA-N 0.000 description 1
- ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 1
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 1
- LTFLDDDGWOVIHY-NAKRPEOUSA-N Val-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N LTFLDDDGWOVIHY-NAKRPEOUSA-N 0.000 description 1
- RUCNAYOMFXRIKJ-DCAQKATOSA-N Val-Ala-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RUCNAYOMFXRIKJ-DCAQKATOSA-N 0.000 description 1
- PFNZJEPSCBAVGX-CYDGBPFRSA-N Val-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N PFNZJEPSCBAVGX-CYDGBPFRSA-N 0.000 description 1
- WITCOKQIPFWQQD-FSPLSTOPSA-N Val-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O WITCOKQIPFWQQD-FSPLSTOPSA-N 0.000 description 1
- OBTCMSPFOITUIJ-FSPLSTOPSA-N Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O OBTCMSPFOITUIJ-FSPLSTOPSA-N 0.000 description 1
- WPSXZFTVLIAPCN-WDSKDSINSA-N Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O WPSXZFTVLIAPCN-WDSKDSINSA-N 0.000 description 1
- CFSSLXZJEMERJY-NRPADANISA-N Val-Gln-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CFSSLXZJEMERJY-NRPADANISA-N 0.000 description 1
- UPJONISHZRADBH-XPUUQOCRSA-N Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UPJONISHZRADBH-XPUUQOCRSA-N 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- WFENBJPLZMPVAX-XVKPBYJWSA-N Val-Gly-Glu Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O WFENBJPLZMPVAX-XVKPBYJWSA-N 0.000 description 1
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
- JVYIGCARISMLMV-HOCLYGCPSA-N Val-Gly-Trp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N JVYIGCARISMLMV-HOCLYGCPSA-N 0.000 description 1
- BNQVUHQWZGTIBX-IUCAKERBSA-N Val-His Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CN=CN1 BNQVUHQWZGTIBX-IUCAKERBSA-N 0.000 description 1
- DLMNFMXSNGTSNJ-PYJNHQTQSA-N Val-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N DLMNFMXSNGTSNJ-PYJNHQTQSA-N 0.000 description 1
- XBRMBDFYOFARST-AVGNSLFASA-N Val-His-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N XBRMBDFYOFARST-AVGNSLFASA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- VENKIVFKIPGEJN-NHCYSSNCSA-N Val-Met-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N VENKIVFKIPGEJN-NHCYSSNCSA-N 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- DOBHJKVVACOQTN-DZKIICNBSA-N Val-Tyr-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=C(O)C=C1 DOBHJKVVACOQTN-DZKIICNBSA-N 0.000 description 1
- RTJPAGFXOWEBAI-SRVKXCTJSA-N Val-Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RTJPAGFXOWEBAI-SRVKXCTJSA-N 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N Valylglycine Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- DVCSNHXRZUVYAM-BQBZGAKWSA-N leu-asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O DVCSNHXRZUVYAM-BQBZGAKWSA-N 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108010043322 lysyl-tryptophyl-alpha-lysine Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108010017798 polymyxin S(1) Proteins 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are improvements in methods for the isolation of endotoxin-binding proteins which are secreted by transfected host cells in appropriate cell culture media.
In its preferred embodiments, the invention comprises addition of a cation exchange material to the media as the means of increasing the yield of recombinant endotoxin-binding proteins, such as bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein.
In its preferred embodiments, the invention comprises addition of a cation exchange material to the media as the means of increasing the yield of recombinant endotoxin-binding proteins, such as bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein.
Description
r CA 02276548 1999-08-09 IHPROVED HETHODS FOR T$E PREPARATION OF
ENDOTOYIN-BINDING PROTEINS
LDOF TgE INVENTION
The present invention generally relates to improved procedures for the preparation of endotoxin-binding proteins by recombinant methods and more to particularly to processes for the large scale production of recombinar~t endotoxin-binding proteins, such as bactericidal/ permeability-increasing (BPI) protein, lipopolysaccharide-binding protein (LHP)) high density lipoprotein, L.imulus anti-LpS factor, 15 tachyplesin, and structurally related proteins using genetically transformed host cells grown in culture, including culture in fermentors. -HIsrCICGROUND OF THE INVENTION
Endotoxin, or lipopolysaccharide, is a 20 component of the cell wall of Gram-negative bacteria and is implicated in the manifestation of acute bacterial infections. Numerous proteins have been reported which bind to the principal form of endotoxir~, lipopolysaccharide ("LPS"). Examples of 2 5 s a c h L P S - b i n d i n g p r o t a i n s a r a bactericidal/permeability-increasing protein ('~BPI
r CA 02276548 1999-08-09 .. 2 _ proteirx") l.ipopolysaccharide-binding protein ("LBP"), high density lipoprotein, and tachyplesin [Nal~amuxa, et al., J. Biol) Chem., 263: 16709-16713 (1988)l.
Certain o~ these proteins share significant structural homology. For example) both sPI and LBP
possess a positively-charged amino terminal region of approximately 25 kDa which is the portion of each molecule which binds to the lipid A portion of LPS. See SChumanzi, et ai., Science, 249:1429-19:31 (1990).
Binding of BPI pxotein to membrane-bound LPS
increases the ezwelope permeability o~ susceptible Gram negative bacteria. Ooi, et al., J. Biol. Chem., 262:14891 (~.987j. BPI protezn also binds to soluble LPS
anal human BPT protein has been isolated from 7.5 polymarphonucJ.ear neutrophils ( "PMNS" ) by acid extraction combined with either ion exchange chromatography or E.
coli a~fin,~.ty chromatography. Elsbach, et al. J. giol.
Chem., 254:11000 (1979); Weiss et al_, Blood, 69:652 (1987). The bolo-BPI protein, isolated from human pMNs has potent bactericidal activity against a broad spectrum of Gram-negative bacteria. ElsbaCh, et al., J. Biol.
Chem., 254:1.1000 {1979). This antibacterial activity appears to be associated with the amino= ~.ermir~.al region of the isolated human holo-BPI protein. In contrast, the carboxyl terminal region of the isolated human BPI
protein displays only slightly detectable anti-bacterial activity. Ooi, et al., J. Exp. Med., 174:549 (1991).
Human DNA encoding BPI has been cloned and the amino acid sequence of the encoded protein has been elucidated [See, Gray et al., J'. Biol. Chem., 264:9505 (1989), hereinafter referred to as "Gray"; U.S. Letters Patent No. 5,198,541 dated March 30, 1993] allowing for the large scale production of recombinant BP'I and biologically active (e. g., amino and carboxyl terminal) fragments thereof. Xnitial attempts to purify recombinant BPI and HPI-related proteins fxom the medium of transfected cells util~.zing traditional protein purification methods provided low yields. Pulse-chase 5 experiments using 3sS labelled methionine and performed on cell cultures of traz~sfected Chinese Hamster Ovary (CHO) cells expressiza.g a recombinant product comprising the amino terminal 199 amino acids of the mature BPI protein (hereinafter rHPX(1-199)] indicated that the recombinant BPI fragment disappeared from the media during 3.5 hours to 7 hours of chase. Preliminary experimental. procedures aimed at determining the basis for this low product yield indicated that the protein product displ-ays significant "sticaciness" and, In fact, adheres to itself, to other Z5 media components (including host cells), and to plastic and glass culture vessels. However, the precise reasons) fox protein loss have yet to be elucidated.
r CA 02276548 1999-08-09 Like 8PT protein, LBP binds to the lipid A
portion of LPS. The bolo-LBP protein is a 60 kD protein secreted by the liver and has been reported to be responsible for delivering LPS to macrophages. Ooi; et al., J. Exp. Med., 7.7~: 649-65 (1991). Unlike BPT
protein, LBP generally enhances the inflammatory response generated by LPS. For example, LBP stimulates LPS-induced tumor necx~osls factor ( ~rTNFr~ ) production.
Of interest to the present invention is the use of ion exchange materials in the isolation and purificatioz~ of proteins and related substances. For example, Centocox Inc. PCT application No. W089/05157 published June 15, 1989, reports the purification and isolation of recombinant immunoglobulins by passing the cell culture medium over a chromatography column, wherein the immunoglobulin is adsorbed onto axi exchange material.
The immundglobulin is then eluted by raising the salt concentration in the column. As another example, published PCT application No. w0 90/087.59 by Robins, et a3.., reports removal of DNA from protein. preparations by incubation in the presence of an anion exchange material.
Wang, Ann. N.Y. Acad. Sci., 413:313-321 (1983) presents the results of ~~hybridrr ferment=ation-extraction procedures for the production and isolation of a model antibiotic, cycloheximide, from fermentation cultures using non-ionic resins and noted that for one resin (XAD-4, Rohm and Haas, Philadelphia, PA) the product was absorbed on the resin surface making it ~~conceivable~~ to harvest the product from the resin.
Due to the utility of endatoxin binding proteins such as BPI protein and LBP as regulators of bacterial infection and the sequelae thereof, there exists a need in the art for improved methods for the isolation of such proteins from cell culture media.
$RIEF SUl~ARY OF THE IN~E
The present invention provides improved methods which facilitate the isolation of endvtoxih-binding proteins, and especially lipid A binding proteins, in high yields.
15_ The improved methods generally comprise the incorporation of a particulate ration exchange material into cell culture medium containing host cells which have been genetically trahsfected with DNA
encoding the endotoxin-binding protein. Such proteins 2o which are secreted into the cell culture medium by said host cells are reversibly bound to said ration exchange material. The canon exchange material with bound protein is then separated from the cell culture medium. Finally, the desired endotoxin-binding 25 protein is then isolated from the ration exchange material.
The improved methods comprise the incorporation of a particulate ration exchange material (preferably S-Sepharose~"particles) into a cell culture medium containing host cells (preferably CHO--Kl or CHO-DG44 Cells) which have been genetically transformed with DNA for expression of endotoxin-binding proteins or fragments thereof. The protein secreted into the cell medium by said host cells .is reversibly bound to said cation exchange material.
The cation exchange material with bound protein is then separated from the cell culture medium. Finally, 1D the protein is isolated from the cation exchange material.
A presently preferred cativn exchange material for practice of the invention is S-Sepharose alzd presently preferred isolation procedures comprise sequentially contacting the canon exchange laaterial with a gradient or steps of increasing ionic strength.
In a preferred embodiment of the invention, the improved methods are applied to the production of recombinant BPI products, including but not limited 2.0 to, bactericidal/permeability-increasing protein and biologically active fragments thereof as well as gpI-related products such as fusion proteins comprising, at their amino terminal, the BfI protein or a biologically active fragment thereof and, at their carboxy teL'~riinal, at least one Constant domain of an immunoglohulxn heavy chain region or an allelic ~ariatlt thereof. Proteins of interest are secreted by genetically transformed host cells which are grown and maintained in a culture medium suitable for growth of host cells and secretion of the protein products.
Also, in another embodiment of the invention, the present improved methods are applied to the isolation of lipopolysaccharide-binding protein and amino-terminal fragments thereof.
The foregoing brief summary illustrates the preferred embodiments of the invention. Numerous aspects and advantages of the present invention will become 1o apparent to the skilled artisan upon reading the following detailed description thereof.
pESCRIPTION OF THE DRAWING
FIGS. lA, 1B, 1C and 1D depict the results of comparative experiments using methods according tv the invention and traditional chromatography methods to isolate the rBPI(1-199) protein.
FIG. 2 depicts the results of the stepwise elution of rBPI(1-99) from S-Sepharose.
FIG. 3 depicts results of Western blot analysis of products prepared according to the invention.
FIG. 4 is a Western blot depicting rBPI-Ig fusion products prepared according to the methods of the present invention.
.FIG. 5 depicts the results of a Cvomassie-stained gel depicting isolation of LBP prepared according to methods of the present invention.
DETAILED DESCRIPTION OF THE INVENTIC~I~i The following detailed description illustrates practice of methods of the invention in the context of recombinant production of three particular endotoxin-binding proteins, an amino-terminal portion of recombinant BPI protein ("rBPI
protein"}) an amino-terminal portion of recombinant LBP ("rLBP"), and rBPI-immunoglobulir~ fusion proteins ("rHPI-Ig fusions") from animal cell cultures. While the practise of the invention is exemplified herein by certain specific endotoxin-binding proteins, it is apparent to the skilled artisan that, due to their general structural and functional similarities, any endotoxin-binding protein may be isolated using methods of the invention. Such proteins include, but are not limited to, polymyxin S, high density lipoprotein, Limulus anti-LPS factor, and tachyplesin.
More specifically, example 1 demonstrates that addition of the ration exchange material, S
Sepharose, to a cell culture medium results in increE~sed yields of rBPI protein. Example 2 provides further results which demonstrate that introduction of the ration exchange material to cell cultures produces increased yields of rBPI protein. Example 3 illustrates practice of the improved methods in the isolation of rSPi-immunoglobulin fusion proteins and Example 4 de7adonstrates the use of a ration exchange material in the isolation of LBP.
-g-Egampla t isolation of recombinant gpI products Methods of the present invention were used to isolate a recombinant HPI protein which is the expression product of DNA encoding the 31-residue signal sequence and the first 199 amino acids of the N-terminus of the mature human BPI, as set out in SEQ
ID NOS: 1 and 2 and is desj~gnated "rBPI(1-199)"
herein. The DisA sequence employed differs from the BPI-encoding DNA sequence reported in Gray, et al., supra, in that the vaiine at position 151 of the rSPI(1-199) expression product is specified by GTG
rather than by GTC as in Gray et~al. and rBPI(1-199) encodes giutamic acid (specifi.ed by GAG) at position 185 rather than lysine (specified by AAG) as reported at that position in Gray et al. Recombinant production of rBPI(1-199) protein is_ reported in Gazzano-Santoro, et al., Infect~an and Immunity, 60:
4754-4761 (1992), wherein the protein is referred to as "rBPI-23".
The host cells employed in this example were CHO-K1 cells transformed with a DNA vector including DNA encoding the initial 199 amino terminal amino acids of human BPI preceded by its endogenous 31 residue secretory signal sequence. The desired expression product, rBPI(1-199), was a biologically active fragment of the human BPI protein comprising the initial 199 amino terminal residues from whi,eh the signal sequence residues were removed in the course of pQSt-translational secretory processing by the host cells.
Two roller bottles containing the transfected CHI host cells in Hams' F12 medium supplemented with 5% fetal bovine serum were prepared and the cells were grown to confluence (approximately 3 days). Once confluency was reached, the Hams Fl2 medium was removed and replaced with 500 ml of HH-CHo serum free medium (Irvine Scientific, Irvine, Ca.).
In the first roller bottle, approximately 8 gm (wet weight) of sterilized S-Sepharose (Pharmacia, fast flow, ~1~-0512-O1, Uppsula, Sweden) was added to one of the roller bottles for 3 days. The S-Sepharose was then isolated in order tv generate a first column.
Growth medium and S-Sepharose resin were removed from roller bottles, pooled and left for at least 15 minutes to allow the S-Sepharose to=_settle to the bottom of the container. The bulk of the medium, clear of resin, was removed by decanting and then filtered through a device, such as a fritted disc, to permit the removal of cells and the retention of the S-Sepharose. Following the decanting of the medium, the S-Sepharose was suspended in an Acetate buffer comprising 20 mM sodium acetate/acetic acid at pH 4.0 Containing 0.1 M NaCl, stirred gently, and allowed to settle for 10 minutes. The buffer was then decanted and the S-Sepharose was transferred in a small volume to an appropriately-sized liquid chromatography column (1 x 10 cm, Econocolumn~ BioRad, Richmond) CA).
..11-The second roller battle contained cells grown under the conditions stated above but in the absence of S-Sepharose. The u~edium from this second roller bottle was removed from the roller bottle. CHO
cells were removed by centrifugation and the clatrified medium was adjusted to contain 20 mM sodium acetate/acetic acid, pH 4Ø The medium was diluted to a conductivity of 10-1S mS/cm and was then loaded onto a second, traditional S-Sepharose column which had bean equilibrated in 2o mM sodium acetate/acetic acid pH 4.0 (Acetate buffer) containing 0.1 M NaCl in order to maximize binding of the xBp=(1-199) protein.
Both the first and the second S-Sepharose columns were washed with 0.1 M NaCl-Acetate buffer until the AZ80 absorbance of the eluate w2~s equal to that of the 0.1 M NaCI-Acetate buffer alone. The protein bound to each column was then eluted in a single step with 1.0 M NaCl-Acetate buffer.
The eluates from both columns ~ were subjected to an ELISA assay wherein samples from the eluates ,.~
were bound to Immulon-2 flat bottom multiwell plates (Dynetech Labs) in the presence of PBS overnight at 4~C. The plates were then washed with 0.05% Tween-20'~
~n PBS, and then incubated with a 1:1000 dilution of rabbit anti-rBPI(1-199) antisera in PBS containing 0.05% Tween-2o for one hour at room temperature.
After incubation) the plate was again washed With 0.05% Tween-?.0 in PBS and the ELISA was developed using the TMB reagent (Pierce Rockford, IL) according to the manufactures instructions and read at 450 nm in an EL309 micxoplate reader (Biotek Instruments, Winoosaci Vt. ) .
The ELISA results revealed that the eluate from the S-sepharose column derived from the cell culture medium produced 3-8 fold stronger reactivity compared to the eluate from the S-Sepharose column to which medium had been added.
Example 2 provides fuxther results, demonstrating that culturing S-Sepharose together with transfected CHO cells increased the yield of rBPI(1 199) protein produced by the transfected cells.
Exasap 1 a 2 puantitative Anal~rsis of Isolation or rBPI(1-1991 In order to more quantitatively demonstrate that the yield of the rHPZ(1-1.99) protein product obtained from the CHO cell cultures in=Example 1 was greater when a cation exchange material was added to the cell culture medium, stained gel and Western analyses were carried out on the eluate samples described above.
Protein samples obtained from the 1.0 M
NaCI-Acetate buffer eluates described in Example 1 were separated by SDS-polyacryl.amide gel electrophoresis (SDS-PAGE). The samp7.es of rBPZ(1-199) were first adjusted to contain less than O_5 M
NaCl and were then precipitated by the addition of ice-cold acetone to a final concentration of 75%. The resulting protein precipitate was then pelleted by centrifugation at greater than 10,000 rpm far 5 to to minutes. The supernatant was removed and the precipitate was suspended in a gel sample buffer containing a M Urea, 2% sDS, 60 mM Tris Hcl at pH 6.8.
The suspended samples and appropriate protein molecular weight standards (BioRad, Richmond, CA and BRL, Bethesda, MD) were heated to 95 C for 3-5 minutes and then loaded onto uniform percentage or gradient percentage polyacrylamide gels (BioRad) and separated using a mini Protean~II gel electrophoresis apparatus (HioRad). Following eJ.ectrophoresis the gels were used directly for Coomassie staining (0.5% Coomassie Brilliant slue-R, 25% isopropanol, ~o% methanol, lo%
acetic acid) or were used for electrotransfer. The proteins which were separated by SDS-PAGE were electrotransferred along with appropriate prestain standard protein (BioRad) onto either nitrocellulose (8A85, Schleicher and Schuell, Keene, NH) or PVDF
(Immobilon-P;~~Millipore, Bedford, MA) membranes. The transfer was achieved in 10% CAPS (cyclohexylamino-1-propane-sulgonic acid), 10% methanol, pH 1.1.5 for 20 minutes at 0.5 amps. The resulting blots were processed using a 1:1000 dilution of rabbit anti-human BPr (holoprotein) antisera and the Western Lite Chemiluminescent Detection Systems (Tropix System, Bedford, MA) according to the manufacturer's instructions. Gelatin (BioRad) at 0.25% was used in place of Tropix I-Blocky and the membranes were not - . - - CA 02276548 1999-08-09 dried following electrotransfer. The processed membranes were exposed to Cronex ~4 film (Dupont) Wilmington, DE).
The results of the stained gel and Western analysis are shown in Figs. 1A-1D, wherein Fig. lA and 1B
respectively present coomassie stain and Western blot analysis of the flow through (FT), 0.1 M NaCl and l.0 M
NaCl e~.uates of columns formed from S-Sephdrose beads incubated with culture medium. Figs. iC and 1D
correspondingly present Coomassie stain and Western blot analysis of eluates from "traditional" columns of S-Sepharose. The arrow in Figs. lA and 1C indicates the region correspot'~ding the molecular weight of the rBPI ( 1-199) protein product. The yield of rHPI(1-199) protein was estimated to be at.least 10-fold higher when the cationic exchange xesin, 5-Sephaxose, had been added to the culture medium during cell growth.
Subsequent Experiments involved the isolation of rBPI(1-199) from 20 to 40 g of s~Sepharose obtained from 3 to 5 roller bottles. The bound samples were eluted with increasing concentrations of NaCl in Acetate buffer. As Shown in Fig. 2, the rHPI(1-199) product, visualized by Coomassie blue staining, is seen as a 23 kd protein in the 0.8, 0.9, 1.0, and 1.5 M NaCI-Acetate buffer eluates from the S-Sepharose columns. Lrittle or no rHPI(1-199) protein was observed in the 0.2 M to 0.7 M NaCl-Acetate buffer eluates. The xesults of the Western Hlot (Figure 3) indicated that the strongest detectable rBPx(1--199) protein signal was obtained in the 0.8 M to 1.0 M NaCI-Acetate buffer eluates of the S-Sepharose columns.
The 1.5 M NaCl eluate froaa the S-Sepharose column also contained protein which was identified as rBPI(1-199) (See Figure 2) right lade). The 1.5 M
NaCl-Acetate buffer eluate from the S-Sepharose column contained protein having molecular weights of approximately 40 kDa and gxeater than 66 kDa (Fig. 2) which, upon treatment with dithiozhreitol, could be reduced to a single band of approximately 23 kDa. The reduced protein was cross-reactive with anti-BPI
antisera and had the N-terminal sequence of correctly processed rHPI(i-199). The 40 kDa and greater than 66 kDa proteins appear to be disulfide-linked multimers of rBPI(1-199).
The aforementioned results indicate that the addition of a cation exchange material to the cell culture medium improved recovery of rBPI(1-199) protein. Zn order to determine optimum concentration of S-Sepharose, 1.25 g to 10 g quantities of S-Sepharose were added to roller bottles containing 5D0 ml culture medium 2ind transfeeted CHO cells and allowed to incubate as described above. The medium containing the Gation exchange material was then poured into columns as described above. The columns were washed with 0.1 M NaC1-Acetate buffer, then with 0.7 M NaCl-Acetate buffer arid the rBPI{1-199) sample was eluted with 1.0 M NaC1-Acetate buffer. The yield of rBPI(1~199) was determined by chromatography on C4 reverse phase HPLC and was essentially constant for 2.5 g, 5.0 g, arid 10 g quantities of S-Sepharose. 'fhe yield was decreased by approximately 50% in roller bottles containing only 1.25 g S-Sepharose per roller bottle.
Example 3 provides results demonstrating that increased yield of rBPI fusion proteins is obtained using methods according to the present invention.
lQ EXAMPLE
Isolatio of rBPZ-Ig k'usion Proteins Host cells employed in this example are CHO-DG44 ce~.ls transfected with a DNA vector comprising DNA
encoding the initial 1.99 amino acids of BPI protein fused to at least one constant region of an immunoglobulin heavy chain_ Transfected CHO-DG44 cells were grown in roller bottles. For eack~ roller bottle) a T150 flask (containin.g 50 ml ~-MEM without nucleosides and 10%
dialyzed fetal bovine serum) was inoculated with transfected Cells and the cells were grown to confluence (approximately 3-4 days). The --cells were then trypsiniaed and transferred into a 90ocm2 roller bottle containing 500 ml Ham's F12 media and 10% fetal bovine serum and grown to confluence for approximately 3 days. Once confluency was reached, the Ham's F12 medium was removed arid replaced with 500 ml HB-CHO serum-free medium (Irvine Scientific, 3rvine, CA) .
S-Sepharose beads, which had first been washed with Dulbecco's phosphate buffered saline (PBS) l0 and autoclaved for 20 minutes at 120°C were added aseptically to the roller bottles. The cells were then incubated at 37~ C for 3 days) at which time the beads and growth medium were removed and left undisturbed for at least 15 minutes. The bulk of the medium, clear of resin, was removed from by decanting and filtered through a device) such as a fritted disc, which allows removal of the cells and retention of the 5-Sepharose. Following the decanting of the medium, the S-Sepharose was suspended in an acetate buffer comprising 20 mM sodium acetate/acetic acid, 0.1 M
NaCI at pH 4.0, stirred gently, and allowed to settle for 10 minutes. The buffer was then decanted and the S-Sepharose was transferred in a small volume to an appropriately-sized liquid chromatography column. An Econocolumn (2.5 x 10 cm, BioRad, Richmond, CA) was used for a 20 to 40 g pooled sample of S-Sepharose collected from 3 to 5 roller bottles. The packed S-Sepharose column Was washed wi~.h o.i M NaCI-acetate buffer until the A280 absorbance of the eluate was equal to that of the O.l M NaCl-acetate buffer alone, with 0.5 M NaCl-acetate buffer, with 1.0 M NaCl-acetate buffer and again with 1.5 M NaCl-acetate buffer.
Additional CHO-DG44 cells were prepared as above except that S-Sepharose beads were not added to the cu3ture medium. Instead, an attempt was made to purify the rBPI fusion expression product utilizing two different protein A coiumns. A first sample of HB-CHO medium (see above) was filtered through a 0.45 ycm filter in order to separate the CHO-DG4a cells from the zest of the medium. The sample was than adjusted ", .
to pH 8.0 and placed on a 1?roSepA ~(Biopracessing) column. A second preparation was placed on an AvidGel""
(Bioproeessing) column. The elution og bath columns was, performed with 25 mM citrate buffer at pH 5 . 5 . No rBPI fusion product was recovered from=-either protein A Column. Nor was any product visualized from the ProSepA column following reduction (Figure 4, lane 1).
However, when the ProSepA and Avidgel columns were stripped with 100 mM citrate buffer at pH 3. D, rBPI
fusion prote~.n was detected as shown respectively in lanes 2 and 3 of Figure 4. Lanes 4-6 of Figure a represent the 0.5 M, 1.0 M, and 1.5 M eluates from the S-Sepharose column. Of the eluates from the s-Sepharose column, the 2.5 M eluate contained material corresponding to a fusion diner of approximately 100 kD.
, CA 02276548 1999-08-09 _19-Example 4 provides results demonstrating that increased product y~.eld of LBP is also obtaiz~ed when cells transfected with DNA encoding LB12 are incubated with a cation exck~ange resin.
isolation Of Lipopolysacch ride-Binding Protein The DNA sequence obtained for the 25 kD amino term3.nal of LBP is shown iz~ SEQ ID NO: 3. That Sequence differs in two regions from the reported sequence of Schumann, et al., Science, 249: 1429_1431 (1990) (SEQ ZD
NO: 4) . Those differez~Ces lead to amino acid differences at pos~.tions 129-232 and at position 149 (an asparagine residue at position 1~k8 is encoded by GAT in Schumanrz, supra and by SAC in SEQ ZD NO: 3). See also, Zncyte 25 Pharmaceuticals Tnc. PCT Appla.cation 93/06228 published April 1, 1.993.
Host cells employed in this example are CHO-DG44 cells transfected with a DNA vector comprising DNA
encoding the initial 197 amino acids of LBP, the expression product.
Transfected DG44 cells were=-grown in roller bottles. For each roller bottle, a T150 flask (containing 50 ml a-ME~I without nucleosides and 100 dialyzed fetal bovine serum) was inoculated with transfected cells and the cells were grown to cox~.fluence (approximately 3-4 days). The cells were then trypsinized and transferred into a 900cmz roller bottle containing 500 ml Ham's F12 media axed 10% fetal bovine serum and grown to confluence for approximately 3 days. Once confluency was reached, the Hams F1z medium was removed and replaced with 500 ml HB-CHO
serum-free medium (Irvine Scientific, Irvirie, CA).
S-Sepharose beads) which had first been washed with PBS and autoclaved for 20 minutes at 120 C were added aseptically to the roller bottles. The cells were then incubated at 37 C for 3 days, at which time the beads and growth medium were removed and left undisturbed for at least 15 minutes. The bulk of the medium, clear of resin, was removed from by decanting and filtered through a device, such as a fritted disc, which allows removal of the cells and retention of the s-Sepharose. Following the decanting of the medium, the S-Sepharose was suspended in an acetate buffer comprising 20 mM sodium acetate/acetic acid, 0.1 M
NaCI at pH 4.0, stirred gently, and allowed to settle for 10 minutes. The buffer was then decanted and the S-Sepharose was transferred in a small volume to an appropriately--sized liguid chromatography column. An 2o Econocolumn (2.5 x 10 cm, BioRad, Richmond, CA) was used for a 2o to 4o g pooled sample of S-Sepharose collected from 3 to 5 roller bottles. The packed 5-Sepharose column was washed with 0.1 M NaCl-acetate buffer until the A280 absorbance of the eluate was equal to that of the 0.1 M NaCl-acetate buffer alone, with o.7 M NaCl-acetate buffer and again with 1 . o M
NaCl-acetate buffer.
Yield of rLBP from cell eult~ares in which S-Seprarose beads were added is shown in Figure 5 which is a Coomassie-stained ge7~ of the 0.7 M (lanes 1 and 3) and 1.0 M (lanes 2 and 4) eluates described above.
As shown in the figure, a significant amount of LBP
eluted at 1.0 M. That S-Sepharose is able to facilitate LBP production from cell cultures is unexpected based on its calculated pI {6.6). In the culture medium used above, in which the pH was approximately 7.0, LBP would be expected, based on its pI, to be uncharged oz- slightly negatively charged and thus unreactive with a cation exchange resin, such as s--sepharose.
Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the foregoing description of the presently preferred embodiments thereof. For example, the concentration of cation exchange material used in the-invention may be varied according to the number and type (i.e., efficiency of production of the recombinant product) of cells used. As another example, while cation exchange materials other than S~Sepharose (e. g., Biorex 7oTM and SP (sulfopropyl) type materials such as Sp-Sephadex as well as CM (carboxymethyl) type materials such as CM Sepharose and CM Sephadex) can be employed in processes of the invention, S-Sepharose was preferred as being most readily handled, subjected to sterilization processing, and the like. As still another example, whl.le the above illustrative examples address recombinant production of endotoxin binding . CA 02276548 1999-08-09 proteins in roller bottles, processes of the invention are readily "scaled up" to production izx fermentors.
Typical fermentation conditions for such processes as applied to production of rBPI(1-199) include use of a 60OL working volume iri a 75OL Chemap'" (woodbury, N.Y.) fern~.entor wherein CHO-KJ. cells transfected with plasmid pING4502 [see, Gazzano et al., supxa7 are grown, in ExCell~' 301 medium (,HRH Scientific) supplemented with 0.05% FBS and 0.01 Antifoam (U Carferm Adjuvant~" 27, Union Carbide) and Z°s SP Sepharose "big beads" (1.00-300 micron diameter, pharmacia) is added. Finally, the precise elution proffiles of recombinant endotoxin-binding proteins isolated according to the invention are expected to vary depending on the precise identity of the protein 25 involved. .~s one example, rBPI(1-199) is readily a.solated from resiza. beads foJ.low~ing a 0 , 7 M NaCl-Acetate buffer wash. However, yields of cysteine replacement analogs of BPI protein such as described in co-owned, co-pending Canadian patent application No. 2,155,00 are enhanced by isolation following a 0.6 M NaCI-Acetate buffer wash. Consequently, the only limitations which.
should be placed upon, the scope of the present invention are those which appear in the appended=claims.
SEQUENCE LISTINiG
(1) GENERAL INFORMATION:
(i) APPLICANT: Grinna, Lynn (ii) TITLE OF INVENTION: Improved Methods for the Preparation of Endotoxin-Binding Proteins (iii) NUMHER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Marshall, O'TOOle, Geretern, Murray & Borun (B) STREET: 6300 Sears Tower, ~33 South Waeker Drive (C) CITY: Chicago (p) STATE: Illinois (E) COUNTRY: USA
(F) ZIP. 60606-6402 (v) COliFUTER READABLE FORM:
(A) MEDIiJM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/HS-DOS
(D) SOFTWARE: PatentIn Release X1.0, Version ,f1.25 (vi) CURRENT APPLIGATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION: -(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: vS 07/885,501 (S) FILING DATE: 19-MAY-1992 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Meyers, Thomas C.
(8) REGISTRATION NUMBER: 36,989 (C) REFERENCE/DOCKET NUMBER: 31405 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 312/47d-6300 (B) TELEFAX: 312/474-0448 (C) TELEX: 25-3856 (2) INFORMATION FOR SEQ ID NO: l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1813 base pairs (B) TYPE: nucleic acid (C) STRANDLDNESSe slngla (D} TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(8) LOCATION: 31..1491 (ix} FEATURE:
(A} NAME/1GEY: mat peptide (8} LOCATIONS 124-_.1491 (xi) 5EQU1;NCE DESCRIPTION: SEQ ID NO:l:
CAGGCCTTGA GGTTTTGGCA
GCTCTGGAGG
ATG
AGA
GAG
AAC
ATG
GCC
AGG
G
Met Arg Glu Asn Met Ala Ar Gly -3 1 $
CCTTGCAACGCG CCG AGATGGGTG TCCCTG ATGGTGCTC GTCGCC ATA
ProCyaAanAla Pro ArqTrpVal SerLeu MetValLeu ValAla Ile GGCACCGCCGTG ACA GCGGCCGTC AACCCT GGCGTCGTG GTCAGG ATC
GlyThrAlaVal Thr AlaAlaVal AanPro GlyValVal ValArg Ile TCCCAGAAGGGC CTG GACTACGCC AGCCAG CAGGGGACG (36CGCT CTG 198 ScrGlnLyeGly Leu AspTyrAla SerGln GlnGlyThr AlaAla Leu CAGAAGGAG.CTG AAG AGGATCAAG ATTCCT GACTACTCA GACAGC TTT
GlnLyeGluLeu Lys ArgIleLye IlePro AepTyrser AepSer Phe ' AAGATCAAGCAT CTT GGGAAGGGG CATTAT AGCTTCTAC AGCATG GAC
LyeIleLyeHie Leu ClyLyeGly HieTyr Ser.phcTyr SerMet Asp b5, 50 55 ATCCGTGAATTC CAG CT'rCCCAGT TCCGAG ATAAGCATG GTGCCC AAT
IleArgGluphe Gln LeuProSer SerGln llaSerMet ValPro Aen Val GAS Leu Lya Ph~ Ser Ile Ser Asn Ala Asn Ile Lys Iie Set Gly AAA TGG AAG GCA CAA AAG AGA TTC TTA AAA ATG AGC GGC AAT 2TT GAC d38 Lys Trp Lys Ala Gln Lys Arg Phe Leu Lye Mpt Ser Gly Aon PhQ Asp _25_ LauSer IleGlu GlyMet 5erileSer AlaAep LeuLye LeuGlySer AanPro ThrSer GlyLye ProThrIle ThrCya SerSer CyaSerSer CACATC AACAGT GTCCAC GTGCACATC TCAAAG AGCAAA GTGGGGTGG
HisIle AanSer ValHis ValHisIle SerLys SerLya ValGlyTrp LeuIle GlaLQU PheHie LyaLyaIle GluSer AlaLeu ArgAsnLye ATGAAC AGCCAG GTCTGC GAGAAAGTG ACCAAT TCTGTA TCCTCCGAG 67s HetAea SerGln ValCys GluLyaVal ThrAat1&erVal SerSerGlu cTGCAA CcTTAT TTCCAG ACTCTGCCA GTAATG ACCAAA ATACATTCT 726 LeuGln ProTyr PheGln.ThrLeupro ValHat ThrLys IleAapSeer ValAla GlyIle AanTyr GlyLeuVal AlaPro ProAla ThrTttrAla GluThr LeuAap ValGln MetLyaGly GluPhe TyrSer GluAsnHia IiiaAan ProPro ProPhe AlaProPre Va1Met GluPhe ProAlaAla HiwAsp ArgHet ValTyr LeuGlyLeu SerAap TyrPhe PheAsnThr AlaGly LeuVal TyrGln GiuAiaGly ValLeu LysHet ThrLeuArg AepAsp HetIle ProLys GluserLys pheArg LeuThr ThrLysPhe PheGly ThrPhe LeuPro GluValAla LyBLye phe~Pro AsnMetLyB
PCT/US93/04752.
IleGlnIle HisVal SerAla serThr ProProHis LeuSer ValGln ProThrGly LeuThr PheTyr proAla ValAapVal GlnAla pheAla GTCCTCCCC AACTCC TCCCTG GCTTCC CTCTTCCTG ATTGGC ATGCAC
ValLQUPro AsnSer SerLeu Alaser LauPheLeu I1QGly HetHie ACAACTGGT TCCATG GAGCTC AGCGCC GAGTcCAAC AGGCTT GTTGGA
ThrThrGly 5er?fetGluVal 8erAla GluSerAsn ArgLeu ValGly GluLeu38 LeuAsp ArgLeu LeuLQU GluLeuLya HiaSer AsnIle GlyProPhe ProVal GluLeu LeuGln AspilaMet AsnTyr IleVal ProIleLeu ValLeu ProArg ValAsn GluLysLeu GlnLys Glyphe CCTCTCCCG ACCCcG GCCAGA GTCCAG CTCTACAAC GTAGTG CTTCAG
laa6 ProLeuFro ThrPro AlaArg ValGln LeuTyrAsn ValVa1 LeuGln CCTCACCAG AACTTC CTGCTG TTCGGT GCAGACGTT GTCTAT AAA
ProaieGln Asnghe Leuyou pheGly AiaAspVal ValTyr Lye AGGGGTGCCG GCTGTGGGGC
GGGGCTGTCA
GCCGCACCTC
ACCGGCTGCC CAGATCTTAA CCRAGAGCCC
TTTCCCCAGG CTTGCAAACT
GAATCCTCTC
TCTTCGACTC CACGAGGAAA CATTATTCAT
AGATTCAGAA TGGAAAAGTG
ATGATCTAAA
CATGGTGTGT CTTTCAAGGG CTAAGGCTGC
ATTTTAGGGA AGAGATATTT
TTATGAGCTT.
TCGTGTTT'CR CATGAAAAAA
ATTGTAACCA
AACTTCTGGT
TTTTTTCATG
TG
2 ~ INFOR~iATZON P'OR SEQ ID NO: 2 (i) SEQUEtICE CHARACTERISTICS:
(A) LEIZGxHs 4A7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linoar (ii) MoLECOLE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
Met Arg Glu Asn Ket Ala Arg Gly Pro Cye Aen Ala Pro Arg Trp Val SBr Leu net Val Leu Val Aln Iie Gly Thr Ala Val Thr Ale Ala Vai Asri Pro Gly Val Val Val Arg ile Ser Gln Lye Giy Leu Asp Tyr Ala Ser Gin Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lye Ile Pro Aap Tyr Ser Asp Ser Phe Lys Ile Lye Hie Leu Gly Lys Gly 35 d0 45 His Tyr ser Phe Tyr Sar l3et Aap Ile Arg Glu Phe Gln Leu Pro Ser Ser Gln ile Ser Met Val Pro Aen Val Gly Leu Lya Phe Ser Ile Sar Aen Rla Asn ile Lye Ile Ser Gly Lye Trp Lyg Ala Gln Lya Arg Phg Leu Lys Met Ser Gly Aan Phe Aap Leu Ser Ile Glu Gly Met Ser Ile Ser Ale. Asp Leu Lya Leu Gly Ser Aen Pro Thr Ser Gly Lye Pro Thr Ile Thr Cya Ser Ser Cys Ser Ser His ile Asn Ser Val His Val His Ile Ser Lys Ser Lye Val Giy Trp Leu Ile Gln Leu Phe Hie Lya Lys ilQ Glu 5er Ala Leu Arg Asn Lya Met Aen Ssr Gln Val Cys Glu Lys Val Thr Asn Sar Val Ser Ser Glu Leu Gln Pro Tyr Phe Gln Thr Leu Yro Val Het Thr Lys Ile Aep Ser Val A1a Gly Ile Aen Tyr Gly Leu Vai Ala Pro Pro Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Het Lye Gly Glu Phi Tyr Ser Glu Asn His Hia Asn Pro Pro Pro Pho Ala pro Pro Val Met Glu Phe Pro Ala Ala Hie Aep Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr Pha phe Aan Thr Ala Gly Leu Val Tyr Gln Glu Ala 260 265 2~0 Gly Val Leu Lya t~cat Thr Leu Arg Aap Asp Met Ile pro Lys G1u Ser Lys phe Arq Leu Thr Thr Lys Pha Phe Gly Thr Phe Leu Pro clu Val Ala Lys Lys Phe Pro Aan tset Lye Ile Gin Ile His Val Ser Ala Ser Thr Pro Pro FIia Lou Ser Val Gln pro Thr G1y Leu Thr Phe Tyr Pro Ala Val Aep Val Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu Ile Gly fief His Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn Rrg Lau Val Gly Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys Iiie Ser Asn Ile Gly Pro Phe pro Val Glu Leu Leu Gln Asp Ila Met Aan T~yr Ile Val Pro Ile Leu Vai Leu Pre Arg Val Aen Glu Lya Lea Gln Lys Gly Phe pro Leu pro Thr pro Ala Arg Val Gln Leu Tyr Asn Val Val Leu Gln Pro Hie Gln Aen Phe Lau Leu Phe Gly Ala Asp Val Val Tyr Lys (2) INFOR?iATION FOR SEQ ID No:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTfi: 591 baee pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iX) FEATURE:
( A ) NAME / 1CEY : CD S
(8) LOCATION: 1..591 ( SEQtJE27CE
xi DESCRIPTION
) :
SEQ
ID
NO:
GCClIACCCCCGCTTG GTCGCC AGGATC ACCGACAAG GGACTG CAGTAT 48 AliAsn ProGlyLe5 ValA~.aArgIle Ti AspLya GlyLeu Gi Tyr r O ~
AlaAla GlnGluGly LQULeu AlaLau G1nSerGlu LeuLeu ArgIy,a ACGCTG ccTGACTTC ACCccc GACTTG AGGATCCCC cACGTC GGCCGT laa ThrLeu ProAspPhe ThrGly AspLeu ArgIlePro HisVal GlyArg GlyArg TyrGluPhe HieSer LeuAsn IleHioSer CysGlu LeuLeu HiaSer AlaLeuArg ProVal ProGly GlnGlyLau SerLeu SerIle 65 70 75 gp sQrAap serSerIla ArgVal GlnGly ArgTrpLya ValArg Lyesar TTCTTC AAACTACAG GGC.TCCTTTGAT GTCAGTGTC AAGGGC ATCAGC 336 PhePhe LyeLeuGln GlySer PheA8p Va1SerVal LyeGly IleSer ATTTcc GTCAACCTC cTCTTG GGCAGC GAGTccTcc CGGAGG cccACA 384 IleSer ValAsnGeu LeuLeu GlySer GluSerSer GlyArg ProThr 115 120 1~5 ValThr AlaSerSer CysSer SerAsp IleAlaAsp ValGlu ValAsp ATGTCG GGAGACTTG GGGTGG CTCT'IGAACCTCTTG CAC'.AAC:CAGATT 480 Met Ser Gly Asp Lau Gly Trp Leu Leu Asn Leu Phe Hia Aan Glr~ Ile Id5 150 155 160 GAG TCC AAG TTC cAG AAA GTA CTG GAG AGC AGG ATT TGC GAA ATG ATC 528 Glu ser Lys Phe Gln Lys Val Leu Glu Ser Arg Ile Cyr Glu Met Ile Gln Lye Ser Val Ser Ser Aep Leu Gln Pro Tyr Leu Gln Thr Leu pro Vnl Thr Thr 61u Ila (2) INFORMATxON FOR 5EQ ID N0:4:
(i) SEQUENCE C'NAgACTERISTICS:
(A) LENGTIi: 197 amino acids T'l~pE: a:pino acid (D) TOPOLOGY: linear ( ii ) ttOLECULE T7CgE: grotein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
Ala Asn Pro Gly Leu Val Ala Arg Ile Thr Aap Lya Gly Leu Gln Tyr Ala Ala Gln Giu Gly Leu Leu Ala Leu Gln Ser Glu Leu Leu Arg Ile Thr Leu Pro Asp Phe Thr Gly Aep Leu Arg Ile Pro Hia Val Gly Arg Gly Arg Tyr Glu Phe His ser LQU Agn ile His Ser Cys Glu Leu Leu F3i~ Ser Ala Leu.Arg Pro Val Pre Gly Gln Gly Leu Ser Leu Ser Ile Ser Asp Ser Ser Ile Arg Val Gln Gly Arg Trp Lya val Arg Lya Ser Phe Phe Lye Leu Gln Gly Ser Phe Aep Val Ser Val Lya Gly Ile Ser Ile Ser Val Aan L8u Leu Leu Gly Ser Glu Ser Ser Gly Arg Pro Thr 1.15 1~0 125 Val Thr Alr SQr Ser. Cye Ser Ser Asp Ile Ala Aep Vdl G1u Val Aop ~31~
Hey ser Gly Asp Leu Gly Trp Leu Leu Aen Leu Phe His Asn Gln Ile Glu Ser Lya Pha Gln Lya Val Leu Glu Ser Arg Zle cys Glu Met Ile Gln Lys Ser Val &er Ser Aop Leu Gln Pro Tyr Leu Gln Thr Leu Arg Val Thr 2hr Olu Ile
ENDOTOYIN-BINDING PROTEINS
LDOF TgE INVENTION
The present invention generally relates to improved procedures for the preparation of endotoxin-binding proteins by recombinant methods and more to particularly to processes for the large scale production of recombinar~t endotoxin-binding proteins, such as bactericidal/ permeability-increasing (BPI) protein, lipopolysaccharide-binding protein (LHP)) high density lipoprotein, L.imulus anti-LpS factor, 15 tachyplesin, and structurally related proteins using genetically transformed host cells grown in culture, including culture in fermentors. -HIsrCICGROUND OF THE INVENTION
Endotoxin, or lipopolysaccharide, is a 20 component of the cell wall of Gram-negative bacteria and is implicated in the manifestation of acute bacterial infections. Numerous proteins have been reported which bind to the principal form of endotoxir~, lipopolysaccharide ("LPS"). Examples of 2 5 s a c h L P S - b i n d i n g p r o t a i n s a r a bactericidal/permeability-increasing protein ('~BPI
r CA 02276548 1999-08-09 .. 2 _ proteirx") l.ipopolysaccharide-binding protein ("LBP"), high density lipoprotein, and tachyplesin [Nal~amuxa, et al., J. Biol) Chem., 263: 16709-16713 (1988)l.
Certain o~ these proteins share significant structural homology. For example) both sPI and LBP
possess a positively-charged amino terminal region of approximately 25 kDa which is the portion of each molecule which binds to the lipid A portion of LPS. See SChumanzi, et ai., Science, 249:1429-19:31 (1990).
Binding of BPI pxotein to membrane-bound LPS
increases the ezwelope permeability o~ susceptible Gram negative bacteria. Ooi, et al., J. Biol. Chem., 262:14891 (~.987j. BPI protezn also binds to soluble LPS
anal human BPT protein has been isolated from 7.5 polymarphonucJ.ear neutrophils ( "PMNS" ) by acid extraction combined with either ion exchange chromatography or E.
coli a~fin,~.ty chromatography. Elsbach, et al. J. giol.
Chem., 254:11000 (1979); Weiss et al_, Blood, 69:652 (1987). The bolo-BPI protein, isolated from human pMNs has potent bactericidal activity against a broad spectrum of Gram-negative bacteria. ElsbaCh, et al., J. Biol.
Chem., 254:1.1000 {1979). This antibacterial activity appears to be associated with the amino= ~.ermir~.al region of the isolated human holo-BPI protein. In contrast, the carboxyl terminal region of the isolated human BPI
protein displays only slightly detectable anti-bacterial activity. Ooi, et al., J. Exp. Med., 174:549 (1991).
Human DNA encoding BPI has been cloned and the amino acid sequence of the encoded protein has been elucidated [See, Gray et al., J'. Biol. Chem., 264:9505 (1989), hereinafter referred to as "Gray"; U.S. Letters Patent No. 5,198,541 dated March 30, 1993] allowing for the large scale production of recombinant BP'I and biologically active (e. g., amino and carboxyl terminal) fragments thereof. Xnitial attempts to purify recombinant BPI and HPI-related proteins fxom the medium of transfected cells util~.zing traditional protein purification methods provided low yields. Pulse-chase 5 experiments using 3sS labelled methionine and performed on cell cultures of traz~sfected Chinese Hamster Ovary (CHO) cells expressiza.g a recombinant product comprising the amino terminal 199 amino acids of the mature BPI protein (hereinafter rHPX(1-199)] indicated that the recombinant BPI fragment disappeared from the media during 3.5 hours to 7 hours of chase. Preliminary experimental. procedures aimed at determining the basis for this low product yield indicated that the protein product displ-ays significant "sticaciness" and, In fact, adheres to itself, to other Z5 media components (including host cells), and to plastic and glass culture vessels. However, the precise reasons) fox protein loss have yet to be elucidated.
r CA 02276548 1999-08-09 Like 8PT protein, LBP binds to the lipid A
portion of LPS. The bolo-LBP protein is a 60 kD protein secreted by the liver and has been reported to be responsible for delivering LPS to macrophages. Ooi; et al., J. Exp. Med., 7.7~: 649-65 (1991). Unlike BPT
protein, LBP generally enhances the inflammatory response generated by LPS. For example, LBP stimulates LPS-induced tumor necx~osls factor ( ~rTNFr~ ) production.
Of interest to the present invention is the use of ion exchange materials in the isolation and purificatioz~ of proteins and related substances. For example, Centocox Inc. PCT application No. W089/05157 published June 15, 1989, reports the purification and isolation of recombinant immunoglobulins by passing the cell culture medium over a chromatography column, wherein the immunoglobulin is adsorbed onto axi exchange material.
The immundglobulin is then eluted by raising the salt concentration in the column. As another example, published PCT application No. w0 90/087.59 by Robins, et a3.., reports removal of DNA from protein. preparations by incubation in the presence of an anion exchange material.
Wang, Ann. N.Y. Acad. Sci., 413:313-321 (1983) presents the results of ~~hybridrr ferment=ation-extraction procedures for the production and isolation of a model antibiotic, cycloheximide, from fermentation cultures using non-ionic resins and noted that for one resin (XAD-4, Rohm and Haas, Philadelphia, PA) the product was absorbed on the resin surface making it ~~conceivable~~ to harvest the product from the resin.
Due to the utility of endatoxin binding proteins such as BPI protein and LBP as regulators of bacterial infection and the sequelae thereof, there exists a need in the art for improved methods for the isolation of such proteins from cell culture media.
$RIEF SUl~ARY OF THE IN~E
The present invention provides improved methods which facilitate the isolation of endvtoxih-binding proteins, and especially lipid A binding proteins, in high yields.
15_ The improved methods generally comprise the incorporation of a particulate ration exchange material into cell culture medium containing host cells which have been genetically trahsfected with DNA
encoding the endotoxin-binding protein. Such proteins 2o which are secreted into the cell culture medium by said host cells are reversibly bound to said ration exchange material. The canon exchange material with bound protein is then separated from the cell culture medium. Finally, the desired endotoxin-binding 25 protein is then isolated from the ration exchange material.
The improved methods comprise the incorporation of a particulate ration exchange material (preferably S-Sepharose~"particles) into a cell culture medium containing host cells (preferably CHO--Kl or CHO-DG44 Cells) which have been genetically transformed with DNA for expression of endotoxin-binding proteins or fragments thereof. The protein secreted into the cell medium by said host cells .is reversibly bound to said cation exchange material.
The cation exchange material with bound protein is then separated from the cell culture medium. Finally, 1D the protein is isolated from the cation exchange material.
A presently preferred cativn exchange material for practice of the invention is S-Sepharose alzd presently preferred isolation procedures comprise sequentially contacting the canon exchange laaterial with a gradient or steps of increasing ionic strength.
In a preferred embodiment of the invention, the improved methods are applied to the production of recombinant BPI products, including but not limited 2.0 to, bactericidal/permeability-increasing protein and biologically active fragments thereof as well as gpI-related products such as fusion proteins comprising, at their amino terminal, the BfI protein or a biologically active fragment thereof and, at their carboxy teL'~riinal, at least one Constant domain of an immunoglohulxn heavy chain region or an allelic ~ariatlt thereof. Proteins of interest are secreted by genetically transformed host cells which are grown and maintained in a culture medium suitable for growth of host cells and secretion of the protein products.
Also, in another embodiment of the invention, the present improved methods are applied to the isolation of lipopolysaccharide-binding protein and amino-terminal fragments thereof.
The foregoing brief summary illustrates the preferred embodiments of the invention. Numerous aspects and advantages of the present invention will become 1o apparent to the skilled artisan upon reading the following detailed description thereof.
pESCRIPTION OF THE DRAWING
FIGS. lA, 1B, 1C and 1D depict the results of comparative experiments using methods according tv the invention and traditional chromatography methods to isolate the rBPI(1-199) protein.
FIG. 2 depicts the results of the stepwise elution of rBPI(1-99) from S-Sepharose.
FIG. 3 depicts results of Western blot analysis of products prepared according to the invention.
FIG. 4 is a Western blot depicting rBPI-Ig fusion products prepared according to the methods of the present invention.
.FIG. 5 depicts the results of a Cvomassie-stained gel depicting isolation of LBP prepared according to methods of the present invention.
DETAILED DESCRIPTION OF THE INVENTIC~I~i The following detailed description illustrates practice of methods of the invention in the context of recombinant production of three particular endotoxin-binding proteins, an amino-terminal portion of recombinant BPI protein ("rBPI
protein"}) an amino-terminal portion of recombinant LBP ("rLBP"), and rBPI-immunoglobulir~ fusion proteins ("rHPI-Ig fusions") from animal cell cultures. While the practise of the invention is exemplified herein by certain specific endotoxin-binding proteins, it is apparent to the skilled artisan that, due to their general structural and functional similarities, any endotoxin-binding protein may be isolated using methods of the invention. Such proteins include, but are not limited to, polymyxin S, high density lipoprotein, Limulus anti-LPS factor, and tachyplesin.
More specifically, example 1 demonstrates that addition of the ration exchange material, S
Sepharose, to a cell culture medium results in increE~sed yields of rBPI protein. Example 2 provides further results which demonstrate that introduction of the ration exchange material to cell cultures produces increased yields of rBPI protein. Example 3 illustrates practice of the improved methods in the isolation of rSPi-immunoglobulin fusion proteins and Example 4 de7adonstrates the use of a ration exchange material in the isolation of LBP.
-g-Egampla t isolation of recombinant gpI products Methods of the present invention were used to isolate a recombinant HPI protein which is the expression product of DNA encoding the 31-residue signal sequence and the first 199 amino acids of the N-terminus of the mature human BPI, as set out in SEQ
ID NOS: 1 and 2 and is desj~gnated "rBPI(1-199)"
herein. The DisA sequence employed differs from the BPI-encoding DNA sequence reported in Gray, et al., supra, in that the vaiine at position 151 of the rSPI(1-199) expression product is specified by GTG
rather than by GTC as in Gray et~al. and rBPI(1-199) encodes giutamic acid (specifi.ed by GAG) at position 185 rather than lysine (specified by AAG) as reported at that position in Gray et al. Recombinant production of rBPI(1-199) protein is_ reported in Gazzano-Santoro, et al., Infect~an and Immunity, 60:
4754-4761 (1992), wherein the protein is referred to as "rBPI-23".
The host cells employed in this example were CHO-K1 cells transformed with a DNA vector including DNA encoding the initial 199 amino terminal amino acids of human BPI preceded by its endogenous 31 residue secretory signal sequence. The desired expression product, rBPI(1-199), was a biologically active fragment of the human BPI protein comprising the initial 199 amino terminal residues from whi,eh the signal sequence residues were removed in the course of pQSt-translational secretory processing by the host cells.
Two roller bottles containing the transfected CHI host cells in Hams' F12 medium supplemented with 5% fetal bovine serum were prepared and the cells were grown to confluence (approximately 3 days). Once confluency was reached, the Hams Fl2 medium was removed and replaced with 500 ml of HH-CHo serum free medium (Irvine Scientific, Irvine, Ca.).
In the first roller bottle, approximately 8 gm (wet weight) of sterilized S-Sepharose (Pharmacia, fast flow, ~1~-0512-O1, Uppsula, Sweden) was added to one of the roller bottles for 3 days. The S-Sepharose was then isolated in order tv generate a first column.
Growth medium and S-Sepharose resin were removed from roller bottles, pooled and left for at least 15 minutes to allow the S-Sepharose to=_settle to the bottom of the container. The bulk of the medium, clear of resin, was removed by decanting and then filtered through a device, such as a fritted disc, to permit the removal of cells and the retention of the S-Sepharose. Following the decanting of the medium, the S-Sepharose was suspended in an Acetate buffer comprising 20 mM sodium acetate/acetic acid at pH 4.0 Containing 0.1 M NaCl, stirred gently, and allowed to settle for 10 minutes. The buffer was then decanted and the S-Sepharose was transferred in a small volume to an appropriately-sized liquid chromatography column (1 x 10 cm, Econocolumn~ BioRad, Richmond) CA).
..11-The second roller battle contained cells grown under the conditions stated above but in the absence of S-Sepharose. The u~edium from this second roller bottle was removed from the roller bottle. CHO
cells were removed by centrifugation and the clatrified medium was adjusted to contain 20 mM sodium acetate/acetic acid, pH 4Ø The medium was diluted to a conductivity of 10-1S mS/cm and was then loaded onto a second, traditional S-Sepharose column which had bean equilibrated in 2o mM sodium acetate/acetic acid pH 4.0 (Acetate buffer) containing 0.1 M NaCl in order to maximize binding of the xBp=(1-199) protein.
Both the first and the second S-Sepharose columns were washed with 0.1 M NaCl-Acetate buffer until the AZ80 absorbance of the eluate w2~s equal to that of the 0.1 M NaCI-Acetate buffer alone. The protein bound to each column was then eluted in a single step with 1.0 M NaCl-Acetate buffer.
The eluates from both columns ~ were subjected to an ELISA assay wherein samples from the eluates ,.~
were bound to Immulon-2 flat bottom multiwell plates (Dynetech Labs) in the presence of PBS overnight at 4~C. The plates were then washed with 0.05% Tween-20'~
~n PBS, and then incubated with a 1:1000 dilution of rabbit anti-rBPI(1-199) antisera in PBS containing 0.05% Tween-2o for one hour at room temperature.
After incubation) the plate was again washed With 0.05% Tween-?.0 in PBS and the ELISA was developed using the TMB reagent (Pierce Rockford, IL) according to the manufactures instructions and read at 450 nm in an EL309 micxoplate reader (Biotek Instruments, Winoosaci Vt. ) .
The ELISA results revealed that the eluate from the S-sepharose column derived from the cell culture medium produced 3-8 fold stronger reactivity compared to the eluate from the S-Sepharose column to which medium had been added.
Example 2 provides fuxther results, demonstrating that culturing S-Sepharose together with transfected CHO cells increased the yield of rBPI(1 199) protein produced by the transfected cells.
Exasap 1 a 2 puantitative Anal~rsis of Isolation or rBPI(1-1991 In order to more quantitatively demonstrate that the yield of the rHPZ(1-1.99) protein product obtained from the CHO cell cultures in=Example 1 was greater when a cation exchange material was added to the cell culture medium, stained gel and Western analyses were carried out on the eluate samples described above.
Protein samples obtained from the 1.0 M
NaCI-Acetate buffer eluates described in Example 1 were separated by SDS-polyacryl.amide gel electrophoresis (SDS-PAGE). The samp7.es of rBPZ(1-199) were first adjusted to contain less than O_5 M
NaCl and were then precipitated by the addition of ice-cold acetone to a final concentration of 75%. The resulting protein precipitate was then pelleted by centrifugation at greater than 10,000 rpm far 5 to to minutes. The supernatant was removed and the precipitate was suspended in a gel sample buffer containing a M Urea, 2% sDS, 60 mM Tris Hcl at pH 6.8.
The suspended samples and appropriate protein molecular weight standards (BioRad, Richmond, CA and BRL, Bethesda, MD) were heated to 95 C for 3-5 minutes and then loaded onto uniform percentage or gradient percentage polyacrylamide gels (BioRad) and separated using a mini Protean~II gel electrophoresis apparatus (HioRad). Following eJ.ectrophoresis the gels were used directly for Coomassie staining (0.5% Coomassie Brilliant slue-R, 25% isopropanol, ~o% methanol, lo%
acetic acid) or were used for electrotransfer. The proteins which were separated by SDS-PAGE were electrotransferred along with appropriate prestain standard protein (BioRad) onto either nitrocellulose (8A85, Schleicher and Schuell, Keene, NH) or PVDF
(Immobilon-P;~~Millipore, Bedford, MA) membranes. The transfer was achieved in 10% CAPS (cyclohexylamino-1-propane-sulgonic acid), 10% methanol, pH 1.1.5 for 20 minutes at 0.5 amps. The resulting blots were processed using a 1:1000 dilution of rabbit anti-human BPr (holoprotein) antisera and the Western Lite Chemiluminescent Detection Systems (Tropix System, Bedford, MA) according to the manufacturer's instructions. Gelatin (BioRad) at 0.25% was used in place of Tropix I-Blocky and the membranes were not - . - - CA 02276548 1999-08-09 dried following electrotransfer. The processed membranes were exposed to Cronex ~4 film (Dupont) Wilmington, DE).
The results of the stained gel and Western analysis are shown in Figs. 1A-1D, wherein Fig. lA and 1B
respectively present coomassie stain and Western blot analysis of the flow through (FT), 0.1 M NaCl and l.0 M
NaCl e~.uates of columns formed from S-Sephdrose beads incubated with culture medium. Figs. iC and 1D
correspondingly present Coomassie stain and Western blot analysis of eluates from "traditional" columns of S-Sepharose. The arrow in Figs. lA and 1C indicates the region correspot'~ding the molecular weight of the rBPI ( 1-199) protein product. The yield of rHPI(1-199) protein was estimated to be at.least 10-fold higher when the cationic exchange xesin, 5-Sephaxose, had been added to the culture medium during cell growth.
Subsequent Experiments involved the isolation of rBPI(1-199) from 20 to 40 g of s~Sepharose obtained from 3 to 5 roller bottles. The bound samples were eluted with increasing concentrations of NaCl in Acetate buffer. As Shown in Fig. 2, the rHPI(1-199) product, visualized by Coomassie blue staining, is seen as a 23 kd protein in the 0.8, 0.9, 1.0, and 1.5 M NaCI-Acetate buffer eluates from the S-Sepharose columns. Lrittle or no rHPI(1-199) protein was observed in the 0.2 M to 0.7 M NaCl-Acetate buffer eluates. The xesults of the Western Hlot (Figure 3) indicated that the strongest detectable rBPx(1--199) protein signal was obtained in the 0.8 M to 1.0 M NaCI-Acetate buffer eluates of the S-Sepharose columns.
The 1.5 M NaCl eluate froaa the S-Sepharose column also contained protein which was identified as rBPI(1-199) (See Figure 2) right lade). The 1.5 M
NaCl-Acetate buffer eluate from the S-Sepharose column contained protein having molecular weights of approximately 40 kDa and gxeater than 66 kDa (Fig. 2) which, upon treatment with dithiozhreitol, could be reduced to a single band of approximately 23 kDa. The reduced protein was cross-reactive with anti-BPI
antisera and had the N-terminal sequence of correctly processed rHPI(i-199). The 40 kDa and greater than 66 kDa proteins appear to be disulfide-linked multimers of rBPI(1-199).
The aforementioned results indicate that the addition of a cation exchange material to the cell culture medium improved recovery of rBPI(1-199) protein. Zn order to determine optimum concentration of S-Sepharose, 1.25 g to 10 g quantities of S-Sepharose were added to roller bottles containing 5D0 ml culture medium 2ind transfeeted CHO cells and allowed to incubate as described above. The medium containing the Gation exchange material was then poured into columns as described above. The columns were washed with 0.1 M NaC1-Acetate buffer, then with 0.7 M NaCl-Acetate buffer arid the rBPI{1-199) sample was eluted with 1.0 M NaC1-Acetate buffer. The yield of rBPI(1~199) was determined by chromatography on C4 reverse phase HPLC and was essentially constant for 2.5 g, 5.0 g, arid 10 g quantities of S-Sepharose. 'fhe yield was decreased by approximately 50% in roller bottles containing only 1.25 g S-Sepharose per roller bottle.
Example 3 provides results demonstrating that increased yield of rBPI fusion proteins is obtained using methods according to the present invention.
lQ EXAMPLE
Isolatio of rBPZ-Ig k'usion Proteins Host cells employed in this example are CHO-DG44 ce~.ls transfected with a DNA vector comprising DNA
encoding the initial 1.99 amino acids of BPI protein fused to at least one constant region of an immunoglobulin heavy chain_ Transfected CHO-DG44 cells were grown in roller bottles. For eack~ roller bottle) a T150 flask (containin.g 50 ml ~-MEM without nucleosides and 10%
dialyzed fetal bovine serum) was inoculated with transfected Cells and the cells were grown to confluence (approximately 3-4 days). The --cells were then trypsiniaed and transferred into a 90ocm2 roller bottle containing 500 ml Ham's F12 media and 10% fetal bovine serum and grown to confluence for approximately 3 days. Once confluency was reached, the Ham's F12 medium was removed arid replaced with 500 ml HB-CHO serum-free medium (Irvine Scientific, 3rvine, CA) .
S-Sepharose beads, which had first been washed with Dulbecco's phosphate buffered saline (PBS) l0 and autoclaved for 20 minutes at 120°C were added aseptically to the roller bottles. The cells were then incubated at 37~ C for 3 days) at which time the beads and growth medium were removed and left undisturbed for at least 15 minutes. The bulk of the medium, clear of resin, was removed from by decanting and filtered through a device) such as a fritted disc, which allows removal of the cells and retention of the 5-Sepharose. Following the decanting of the medium, the S-Sepharose was suspended in an acetate buffer comprising 20 mM sodium acetate/acetic acid, 0.1 M
NaCI at pH 4.0, stirred gently, and allowed to settle for 10 minutes. The buffer was then decanted and the S-Sepharose was transferred in a small volume to an appropriately-sized liquid chromatography column. An Econocolumn (2.5 x 10 cm, BioRad, Richmond, CA) was used for a 20 to 40 g pooled sample of S-Sepharose collected from 3 to 5 roller bottles. The packed S-Sepharose column Was washed wi~.h o.i M NaCI-acetate buffer until the A280 absorbance of the eluate was equal to that of the O.l M NaCl-acetate buffer alone, with 0.5 M NaCl-acetate buffer, with 1.0 M NaCl-acetate buffer and again with 1.5 M NaCl-acetate buffer.
Additional CHO-DG44 cells were prepared as above except that S-Sepharose beads were not added to the cu3ture medium. Instead, an attempt was made to purify the rBPI fusion expression product utilizing two different protein A coiumns. A first sample of HB-CHO medium (see above) was filtered through a 0.45 ycm filter in order to separate the CHO-DG4a cells from the zest of the medium. The sample was than adjusted ", .
to pH 8.0 and placed on a 1?roSepA ~(Biopracessing) column. A second preparation was placed on an AvidGel""
(Bioproeessing) column. The elution og bath columns was, performed with 25 mM citrate buffer at pH 5 . 5 . No rBPI fusion product was recovered from=-either protein A Column. Nor was any product visualized from the ProSepA column following reduction (Figure 4, lane 1).
However, when the ProSepA and Avidgel columns were stripped with 100 mM citrate buffer at pH 3. D, rBPI
fusion prote~.n was detected as shown respectively in lanes 2 and 3 of Figure 4. Lanes 4-6 of Figure a represent the 0.5 M, 1.0 M, and 1.5 M eluates from the S-Sepharose column. Of the eluates from the s-Sepharose column, the 2.5 M eluate contained material corresponding to a fusion diner of approximately 100 kD.
, CA 02276548 1999-08-09 _19-Example 4 provides results demonstrating that increased product y~.eld of LBP is also obtaiz~ed when cells transfected with DNA encoding LB12 are incubated with a cation exck~ange resin.
isolation Of Lipopolysacch ride-Binding Protein The DNA sequence obtained for the 25 kD amino term3.nal of LBP is shown iz~ SEQ ID NO: 3. That Sequence differs in two regions from the reported sequence of Schumann, et al., Science, 249: 1429_1431 (1990) (SEQ ZD
NO: 4) . Those differez~Ces lead to amino acid differences at pos~.tions 129-232 and at position 149 (an asparagine residue at position 1~k8 is encoded by GAT in Schumanrz, supra and by SAC in SEQ ZD NO: 3). See also, Zncyte 25 Pharmaceuticals Tnc. PCT Appla.cation 93/06228 published April 1, 1.993.
Host cells employed in this example are CHO-DG44 cells transfected with a DNA vector comprising DNA
encoding the initial 197 amino acids of LBP, the expression product.
Transfected DG44 cells were=-grown in roller bottles. For each roller bottle, a T150 flask (containing 50 ml a-ME~I without nucleosides and 100 dialyzed fetal bovine serum) was inoculated with transfected cells and the cells were grown to cox~.fluence (approximately 3-4 days). The cells were then trypsinized and transferred into a 900cmz roller bottle containing 500 ml Ham's F12 media axed 10% fetal bovine serum and grown to confluence for approximately 3 days. Once confluency was reached, the Hams F1z medium was removed and replaced with 500 ml HB-CHO
serum-free medium (Irvine Scientific, Irvirie, CA).
S-Sepharose beads) which had first been washed with PBS and autoclaved for 20 minutes at 120 C were added aseptically to the roller bottles. The cells were then incubated at 37 C for 3 days, at which time the beads and growth medium were removed and left undisturbed for at least 15 minutes. The bulk of the medium, clear of resin, was removed from by decanting and filtered through a device, such as a fritted disc, which allows removal of the cells and retention of the s-Sepharose. Following the decanting of the medium, the S-Sepharose was suspended in an acetate buffer comprising 20 mM sodium acetate/acetic acid, 0.1 M
NaCI at pH 4.0, stirred gently, and allowed to settle for 10 minutes. The buffer was then decanted and the S-Sepharose was transferred in a small volume to an appropriately--sized liguid chromatography column. An 2o Econocolumn (2.5 x 10 cm, BioRad, Richmond, CA) was used for a 2o to 4o g pooled sample of S-Sepharose collected from 3 to 5 roller bottles. The packed 5-Sepharose column was washed with 0.1 M NaCl-acetate buffer until the A280 absorbance of the eluate was equal to that of the 0.1 M NaCl-acetate buffer alone, with o.7 M NaCl-acetate buffer and again with 1 . o M
NaCl-acetate buffer.
Yield of rLBP from cell eult~ares in which S-Seprarose beads were added is shown in Figure 5 which is a Coomassie-stained ge7~ of the 0.7 M (lanes 1 and 3) and 1.0 M (lanes 2 and 4) eluates described above.
As shown in the figure, a significant amount of LBP
eluted at 1.0 M. That S-Sepharose is able to facilitate LBP production from cell cultures is unexpected based on its calculated pI {6.6). In the culture medium used above, in which the pH was approximately 7.0, LBP would be expected, based on its pI, to be uncharged oz- slightly negatively charged and thus unreactive with a cation exchange resin, such as s--sepharose.
Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the foregoing description of the presently preferred embodiments thereof. For example, the concentration of cation exchange material used in the-invention may be varied according to the number and type (i.e., efficiency of production of the recombinant product) of cells used. As another example, while cation exchange materials other than S~Sepharose (e. g., Biorex 7oTM and SP (sulfopropyl) type materials such as Sp-Sephadex as well as CM (carboxymethyl) type materials such as CM Sepharose and CM Sephadex) can be employed in processes of the invention, S-Sepharose was preferred as being most readily handled, subjected to sterilization processing, and the like. As still another example, whl.le the above illustrative examples address recombinant production of endotoxin binding . CA 02276548 1999-08-09 proteins in roller bottles, processes of the invention are readily "scaled up" to production izx fermentors.
Typical fermentation conditions for such processes as applied to production of rBPI(1-199) include use of a 60OL working volume iri a 75OL Chemap'" (woodbury, N.Y.) fern~.entor wherein CHO-KJ. cells transfected with plasmid pING4502 [see, Gazzano et al., supxa7 are grown, in ExCell~' 301 medium (,HRH Scientific) supplemented with 0.05% FBS and 0.01 Antifoam (U Carferm Adjuvant~" 27, Union Carbide) and Z°s SP Sepharose "big beads" (1.00-300 micron diameter, pharmacia) is added. Finally, the precise elution proffiles of recombinant endotoxin-binding proteins isolated according to the invention are expected to vary depending on the precise identity of the protein 25 involved. .~s one example, rBPI(1-199) is readily a.solated from resiza. beads foJ.low~ing a 0 , 7 M NaCl-Acetate buffer wash. However, yields of cysteine replacement analogs of BPI protein such as described in co-owned, co-pending Canadian patent application No. 2,155,00 are enhanced by isolation following a 0.6 M NaCI-Acetate buffer wash. Consequently, the only limitations which.
should be placed upon, the scope of the present invention are those which appear in the appended=claims.
SEQUENCE LISTINiG
(1) GENERAL INFORMATION:
(i) APPLICANT: Grinna, Lynn (ii) TITLE OF INVENTION: Improved Methods for the Preparation of Endotoxin-Binding Proteins (iii) NUMHER OF SEQUENCES: 4 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Marshall, O'TOOle, Geretern, Murray & Borun (B) STREET: 6300 Sears Tower, ~33 South Waeker Drive (C) CITY: Chicago (p) STATE: Illinois (E) COUNTRY: USA
(F) ZIP. 60606-6402 (v) COliFUTER READABLE FORM:
(A) MEDIiJM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/HS-DOS
(D) SOFTWARE: PatentIn Release X1.0, Version ,f1.25 (vi) CURRENT APPLIGATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION: -(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: vS 07/885,501 (S) FILING DATE: 19-MAY-1992 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Meyers, Thomas C.
(8) REGISTRATION NUMBER: 36,989 (C) REFERENCE/DOCKET NUMBER: 31405 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 312/47d-6300 (B) TELEFAX: 312/474-0448 (C) TELEX: 25-3856 (2) INFORMATION FOR SEQ ID NO: l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1813 base pairs (B) TYPE: nucleic acid (C) STRANDLDNESSe slngla (D} TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(8) LOCATION: 31..1491 (ix} FEATURE:
(A} NAME/1GEY: mat peptide (8} LOCATIONS 124-_.1491 (xi) 5EQU1;NCE DESCRIPTION: SEQ ID NO:l:
CAGGCCTTGA GGTTTTGGCA
GCTCTGGAGG
ATG
AGA
GAG
AAC
ATG
GCC
AGG
G
Met Arg Glu Asn Met Ala Ar Gly -3 1 $
CCTTGCAACGCG CCG AGATGGGTG TCCCTG ATGGTGCTC GTCGCC ATA
ProCyaAanAla Pro ArqTrpVal SerLeu MetValLeu ValAla Ile GGCACCGCCGTG ACA GCGGCCGTC AACCCT GGCGTCGTG GTCAGG ATC
GlyThrAlaVal Thr AlaAlaVal AanPro GlyValVal ValArg Ile TCCCAGAAGGGC CTG GACTACGCC AGCCAG CAGGGGACG (36CGCT CTG 198 ScrGlnLyeGly Leu AspTyrAla SerGln GlnGlyThr AlaAla Leu CAGAAGGAG.CTG AAG AGGATCAAG ATTCCT GACTACTCA GACAGC TTT
GlnLyeGluLeu Lys ArgIleLye IlePro AepTyrser AepSer Phe ' AAGATCAAGCAT CTT GGGAAGGGG CATTAT AGCTTCTAC AGCATG GAC
LyeIleLyeHie Leu ClyLyeGly HieTyr Ser.phcTyr SerMet Asp b5, 50 55 ATCCGTGAATTC CAG CT'rCCCAGT TCCGAG ATAAGCATG GTGCCC AAT
IleArgGluphe Gln LeuProSer SerGln llaSerMet ValPro Aen Val GAS Leu Lya Ph~ Ser Ile Ser Asn Ala Asn Ile Lys Iie Set Gly AAA TGG AAG GCA CAA AAG AGA TTC TTA AAA ATG AGC GGC AAT 2TT GAC d38 Lys Trp Lys Ala Gln Lys Arg Phe Leu Lye Mpt Ser Gly Aon PhQ Asp _25_ LauSer IleGlu GlyMet 5erileSer AlaAep LeuLye LeuGlySer AanPro ThrSer GlyLye ProThrIle ThrCya SerSer CyaSerSer CACATC AACAGT GTCCAC GTGCACATC TCAAAG AGCAAA GTGGGGTGG
HisIle AanSer ValHis ValHisIle SerLys SerLya ValGlyTrp LeuIle GlaLQU PheHie LyaLyaIle GluSer AlaLeu ArgAsnLye ATGAAC AGCCAG GTCTGC GAGAAAGTG ACCAAT TCTGTA TCCTCCGAG 67s HetAea SerGln ValCys GluLyaVal ThrAat1&erVal SerSerGlu cTGCAA CcTTAT TTCCAG ACTCTGCCA GTAATG ACCAAA ATACATTCT 726 LeuGln ProTyr PheGln.ThrLeupro ValHat ThrLys IleAapSeer ValAla GlyIle AanTyr GlyLeuVal AlaPro ProAla ThrTttrAla GluThr LeuAap ValGln MetLyaGly GluPhe TyrSer GluAsnHia IiiaAan ProPro ProPhe AlaProPre Va1Met GluPhe ProAlaAla HiwAsp ArgHet ValTyr LeuGlyLeu SerAap TyrPhe PheAsnThr AlaGly LeuVal TyrGln GiuAiaGly ValLeu LysHet ThrLeuArg AepAsp HetIle ProLys GluserLys pheArg LeuThr ThrLysPhe PheGly ThrPhe LeuPro GluValAla LyBLye phe~Pro AsnMetLyB
PCT/US93/04752.
IleGlnIle HisVal SerAla serThr ProProHis LeuSer ValGln ProThrGly LeuThr PheTyr proAla ValAapVal GlnAla pheAla GTCCTCCCC AACTCC TCCCTG GCTTCC CTCTTCCTG ATTGGC ATGCAC
ValLQUPro AsnSer SerLeu Alaser LauPheLeu I1QGly HetHie ACAACTGGT TCCATG GAGCTC AGCGCC GAGTcCAAC AGGCTT GTTGGA
ThrThrGly 5er?fetGluVal 8erAla GluSerAsn ArgLeu ValGly GluLeu38 LeuAsp ArgLeu LeuLQU GluLeuLya HiaSer AsnIle GlyProPhe ProVal GluLeu LeuGln AspilaMet AsnTyr IleVal ProIleLeu ValLeu ProArg ValAsn GluLysLeu GlnLys Glyphe CCTCTCCCG ACCCcG GCCAGA GTCCAG CTCTACAAC GTAGTG CTTCAG
laa6 ProLeuFro ThrPro AlaArg ValGln LeuTyrAsn ValVa1 LeuGln CCTCACCAG AACTTC CTGCTG TTCGGT GCAGACGTT GTCTAT AAA
ProaieGln Asnghe Leuyou pheGly AiaAspVal ValTyr Lye AGGGGTGCCG GCTGTGGGGC
GGGGCTGTCA
GCCGCACCTC
ACCGGCTGCC CAGATCTTAA CCRAGAGCCC
TTTCCCCAGG CTTGCAAACT
GAATCCTCTC
TCTTCGACTC CACGAGGAAA CATTATTCAT
AGATTCAGAA TGGAAAAGTG
ATGATCTAAA
CATGGTGTGT CTTTCAAGGG CTAAGGCTGC
ATTTTAGGGA AGAGATATTT
TTATGAGCTT.
TCGTGTTT'CR CATGAAAAAA
ATTGTAACCA
AACTTCTGGT
TTTTTTCATG
TG
2 ~ INFOR~iATZON P'OR SEQ ID NO: 2 (i) SEQUEtICE CHARACTERISTICS:
(A) LEIZGxHs 4A7 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linoar (ii) MoLECOLE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
Met Arg Glu Asn Ket Ala Arg Gly Pro Cye Aen Ala Pro Arg Trp Val SBr Leu net Val Leu Val Aln Iie Gly Thr Ala Val Thr Ale Ala Vai Asri Pro Gly Val Val Val Arg ile Ser Gln Lye Giy Leu Asp Tyr Ala Ser Gin Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lye Ile Pro Aap Tyr Ser Asp Ser Phe Lys Ile Lye Hie Leu Gly Lys Gly 35 d0 45 His Tyr ser Phe Tyr Sar l3et Aap Ile Arg Glu Phe Gln Leu Pro Ser Ser Gln ile Ser Met Val Pro Aen Val Gly Leu Lya Phe Ser Ile Sar Aen Rla Asn ile Lye Ile Ser Gly Lye Trp Lyg Ala Gln Lya Arg Phg Leu Lys Met Ser Gly Aan Phe Aap Leu Ser Ile Glu Gly Met Ser Ile Ser Ale. Asp Leu Lya Leu Gly Ser Aen Pro Thr Ser Gly Lye Pro Thr Ile Thr Cya Ser Ser Cys Ser Ser His ile Asn Ser Val His Val His Ile Ser Lys Ser Lye Val Giy Trp Leu Ile Gln Leu Phe Hie Lya Lys ilQ Glu 5er Ala Leu Arg Asn Lya Met Aen Ssr Gln Val Cys Glu Lys Val Thr Asn Sar Val Ser Ser Glu Leu Gln Pro Tyr Phe Gln Thr Leu Yro Val Het Thr Lys Ile Aep Ser Val A1a Gly Ile Aen Tyr Gly Leu Vai Ala Pro Pro Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Het Lye Gly Glu Phi Tyr Ser Glu Asn His Hia Asn Pro Pro Pro Pho Ala pro Pro Val Met Glu Phe Pro Ala Ala Hie Aep Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr Pha phe Aan Thr Ala Gly Leu Val Tyr Gln Glu Ala 260 265 2~0 Gly Val Leu Lya t~cat Thr Leu Arg Aap Asp Met Ile pro Lys G1u Ser Lys phe Arq Leu Thr Thr Lys Pha Phe Gly Thr Phe Leu Pro clu Val Ala Lys Lys Phe Pro Aan tset Lye Ile Gin Ile His Val Ser Ala Ser Thr Pro Pro FIia Lou Ser Val Gln pro Thr G1y Leu Thr Phe Tyr Pro Ala Val Aep Val Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu Ile Gly fief His Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn Rrg Lau Val Gly Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys Iiie Ser Asn Ile Gly Pro Phe pro Val Glu Leu Leu Gln Asp Ila Met Aan T~yr Ile Val Pro Ile Leu Vai Leu Pre Arg Val Aen Glu Lya Lea Gln Lys Gly Phe pro Leu pro Thr pro Ala Arg Val Gln Leu Tyr Asn Val Val Leu Gln Pro Hie Gln Aen Phe Lau Leu Phe Gly Ala Asp Val Val Tyr Lys (2) INFOR?iATION FOR SEQ ID No:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTfi: 591 baee pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iX) FEATURE:
( A ) NAME / 1CEY : CD S
(8) LOCATION: 1..591 ( SEQtJE27CE
xi DESCRIPTION
) :
SEQ
ID
NO:
GCClIACCCCCGCTTG GTCGCC AGGATC ACCGACAAG GGACTG CAGTAT 48 AliAsn ProGlyLe5 ValA~.aArgIle Ti AspLya GlyLeu Gi Tyr r O ~
AlaAla GlnGluGly LQULeu AlaLau G1nSerGlu LeuLeu ArgIy,a ACGCTG ccTGACTTC ACCccc GACTTG AGGATCCCC cACGTC GGCCGT laa ThrLeu ProAspPhe ThrGly AspLeu ArgIlePro HisVal GlyArg GlyArg TyrGluPhe HieSer LeuAsn IleHioSer CysGlu LeuLeu HiaSer AlaLeuArg ProVal ProGly GlnGlyLau SerLeu SerIle 65 70 75 gp sQrAap serSerIla ArgVal GlnGly ArgTrpLya ValArg Lyesar TTCTTC AAACTACAG GGC.TCCTTTGAT GTCAGTGTC AAGGGC ATCAGC 336 PhePhe LyeLeuGln GlySer PheA8p Va1SerVal LyeGly IleSer ATTTcc GTCAACCTC cTCTTG GGCAGC GAGTccTcc CGGAGG cccACA 384 IleSer ValAsnGeu LeuLeu GlySer GluSerSer GlyArg ProThr 115 120 1~5 ValThr AlaSerSer CysSer SerAsp IleAlaAsp ValGlu ValAsp ATGTCG GGAGACTTG GGGTGG CTCT'IGAACCTCTTG CAC'.AAC:CAGATT 480 Met Ser Gly Asp Lau Gly Trp Leu Leu Asn Leu Phe Hia Aan Glr~ Ile Id5 150 155 160 GAG TCC AAG TTC cAG AAA GTA CTG GAG AGC AGG ATT TGC GAA ATG ATC 528 Glu ser Lys Phe Gln Lys Val Leu Glu Ser Arg Ile Cyr Glu Met Ile Gln Lye Ser Val Ser Ser Aep Leu Gln Pro Tyr Leu Gln Thr Leu pro Vnl Thr Thr 61u Ila (2) INFORMATxON FOR 5EQ ID N0:4:
(i) SEQUENCE C'NAgACTERISTICS:
(A) LENGTIi: 197 amino acids T'l~pE: a:pino acid (D) TOPOLOGY: linear ( ii ) ttOLECULE T7CgE: grotein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
Ala Asn Pro Gly Leu Val Ala Arg Ile Thr Aap Lya Gly Leu Gln Tyr Ala Ala Gln Giu Gly Leu Leu Ala Leu Gln Ser Glu Leu Leu Arg Ile Thr Leu Pro Asp Phe Thr Gly Aep Leu Arg Ile Pro Hia Val Gly Arg Gly Arg Tyr Glu Phe His ser LQU Agn ile His Ser Cys Glu Leu Leu F3i~ Ser Ala Leu.Arg Pro Val Pre Gly Gln Gly Leu Ser Leu Ser Ile Ser Asp Ser Ser Ile Arg Val Gln Gly Arg Trp Lya val Arg Lya Ser Phe Phe Lye Leu Gln Gly Ser Phe Aep Val Ser Val Lya Gly Ile Ser Ile Ser Val Aan L8u Leu Leu Gly Ser Glu Ser Ser Gly Arg Pro Thr 1.15 1~0 125 Val Thr Alr SQr Ser. Cye Ser Ser Asp Ile Ala Aep Vdl G1u Val Aop ~31~
Hey ser Gly Asp Leu Gly Trp Leu Leu Aen Leu Phe His Asn Gln Ile Glu Ser Lya Pha Gln Lya Val Leu Glu Ser Arg Zle cys Glu Met Ile Gln Lys Ser Val &er Ser Aop Leu Gln Pro Tyr Leu Gln Thr Leu Arg Val Thr 2hr Olu Ile
Claims (7)
1. A hybrid fusion protein comprising, at its amino terminal, bactericidal/permeability-increasing protein (BPI) or a biologically active fragment thereof and, at its carboxy terminal, at least one constant domain of an immunoglobin heavy chain region or an allelic variant thereof.
2. The hybrid fusion protein of claim 1, wherein the biologically active fragment of BPI consists of amino acid residues 1 through 199 of BPI
3. DNA encoding the hybrid fusion protein of claim 1 or claim 2.
4. A vector comprising the DNA of claim 3.
5. A host cell transformed or transfected with the DNA of claim 3 in a manner allowing expression in the host cell of the encoded hybrid fusion protein.
6. A method of producing the hybrid fusion protein of claim 1 or claim 2, comprising the step of growing the host cell of claim 14 in a suitable culture medium and isolating the hybrid fusion protein from the host cell culture.
7. The hybrid fusion protein produced according to the method of claim 6.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88550192A | 1992-05-19 | 1992-05-19 | |
US07/885,501 | 1992-05-19 | ||
PCT/US1993/004752 WO1993023540A2 (en) | 1992-05-19 | 1993-05-19 | Improved methods for the preparation of endotoxin-binding proteins |
CN93109452A CN1060216C (en) | 1992-05-19 | 1993-06-21 | Improved methods for the preparation of endotoxinbinding proteins |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002136208A Division CA2136208C (en) | 1992-05-19 | 1993-05-19 | Improved methods for the preparation of endotoxin-binding proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2276548A1 CA2276548A1 (en) | 1993-11-25 |
CA2276548C true CA2276548C (en) | 2001-07-31 |
Family
ID=36829817
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002276548A Expired - Fee Related CA2276548C (en) | 1992-05-19 | 1993-05-19 | Improved methods for the preparation of endotoxin-binding proteins |
CA002136208A Expired - Fee Related CA2136208C (en) | 1992-05-19 | 1993-05-19 | Improved methods for the preparation of endotoxin-binding proteins |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002136208A Expired - Fee Related CA2136208C (en) | 1992-05-19 | 1993-05-19 | Improved methods for the preparation of endotoxin-binding proteins |
Country Status (13)
Country | Link |
---|---|
US (1) | US5439807A (en) |
EP (1) | EP0642579B1 (en) |
JP (2) | JP3391453B2 (en) |
CN (1) | CN1060216C (en) |
AT (1) | ATE178652T1 (en) |
AU (1) | AU669723B2 (en) |
CA (2) | CA2276548C (en) |
DE (1) | DE69324359T2 (en) |
DK (1) | DK0642579T3 (en) |
ES (1) | ES2132239T3 (en) |
GR (1) | GR3030419T3 (en) |
HK (1) | HK1014198A1 (en) |
WO (1) | WO1993023540A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
EP0682524B1 (en) * | 1993-02-02 | 2001-10-04 | XOMA Technology Ltd. | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
US5627153A (en) * | 1994-01-14 | 1997-05-06 | Xoma Corporation | Anti-fungal methods and materials |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US5731415A (en) * | 1993-06-17 | 1998-03-24 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
AU7330994A (en) * | 1993-07-14 | 1995-02-13 | Xoma Corporation | Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
CN1133634A (en) * | 1993-09-22 | 1996-10-16 | 爱克斯欧玛公司 | Method for quantifying BPI in body fluids |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
WO1995008344A1 (en) * | 1993-09-22 | 1995-03-30 | Xoma Corporation | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic |
PT754050E (en) * | 1994-01-14 | 2002-11-29 | Xoma Technology Ltd | METHODS AND MATERIALS AGAINST GRAM-POSITIVE BACTERIA |
US5447913A (en) * | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5578568A (en) * | 1994-04-22 | 1996-11-26 | Xoma Corporation | Method of treating conditions associated with intestinal ischemia/reperfusion |
US5932544A (en) | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
AU727085B2 (en) * | 1995-07-20 | 2000-11-30 | Xoma Corporation | Anti-fungal peptides |
US5741779A (en) * | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
CN1236320A (en) * | 1996-05-10 | 1999-11-24 | 爱克斯欧玛公司 | Therapeutic uses of BPI protein products for human meningococcemia |
US5945399A (en) * | 1996-05-23 | 1999-08-31 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US6482796B2 (en) * | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US6719973B1 (en) | 1998-12-24 | 2004-04-13 | National University Of Singapore | Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial and anti-endotoxin therapeutics |
EP1224299B2 (en) * | 1999-10-15 | 2019-10-16 | National University Of Singapore | Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial and anti-endotoxin therapeutics |
EP1492874B1 (en) | 2002-03-29 | 2011-01-19 | XOMA Technology Ltd. | Multigenic vector plasmids and methods for increasing expression of recombinant polypeptides |
EP1741440A1 (en) | 2005-07-08 | 2007-01-10 | Mellitus S.L. | Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders |
GB201319621D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
GB201319620D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
CN105866080B (en) * | 2016-04-05 | 2019-11-12 | 中国科学院苏州生物医学工程技术研究所 | Recombinate three factor agents of horseshoe crab and its endotoxic method of detection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
US5118796A (en) * | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
EP0379549B1 (en) * | 1988-06-23 | 1995-12-27 | Associates Of Cape Cod, Inc. | Endotoxin binding protein and uses thereof |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
-
1993
- 1993-05-19 CA CA002276548A patent/CA2276548C/en not_active Expired - Fee Related
- 1993-05-19 DK DK93913992T patent/DK0642579T3/en active
- 1993-05-19 US US08/072,063 patent/US5439807A/en not_active Expired - Lifetime
- 1993-05-19 AU AU43820/93A patent/AU669723B2/en not_active Ceased
- 1993-05-19 JP JP50361794A patent/JP3391453B2/en not_active Expired - Fee Related
- 1993-05-19 EP EP93913992A patent/EP0642579B1/en not_active Expired - Lifetime
- 1993-05-19 CA CA002136208A patent/CA2136208C/en not_active Expired - Fee Related
- 1993-05-19 ES ES93913992T patent/ES2132239T3/en not_active Expired - Lifetime
- 1993-05-19 WO PCT/US1993/004752 patent/WO1993023540A2/en active IP Right Grant
- 1993-05-19 DE DE69324359T patent/DE69324359T2/en not_active Expired - Fee Related
- 1993-05-19 AT AT93913992T patent/ATE178652T1/en not_active IP Right Cessation
- 1993-06-21 CN CN93109452A patent/CN1060216C/en not_active Expired - Fee Related
-
1998
- 1998-12-24 HK HK98115464A patent/HK1014198A1/en not_active IP Right Cessation
-
1999
- 1999-06-03 GR GR990401503T patent/GR3030419T3/en unknown
-
2002
- 2002-10-15 JP JP2002300374A patent/JP2003125794A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
HK1014198A1 (en) | 1999-09-24 |
AU669723B2 (en) | 1996-06-20 |
CN1060216C (en) | 2001-01-03 |
JP3391453B2 (en) | 2003-03-31 |
CN1096822A (en) | 1994-12-28 |
JP2003125794A (en) | 2003-05-07 |
DE69324359D1 (en) | 1999-05-12 |
CA2136208A1 (en) | 1993-11-25 |
DE69324359T2 (en) | 1999-11-04 |
EP0642579B1 (en) | 1999-04-07 |
AU4382093A (en) | 1993-12-13 |
DK0642579T3 (en) | 1999-10-18 |
EP0642579A1 (en) | 1995-03-15 |
ATE178652T1 (en) | 1999-04-15 |
WO1993023540A2 (en) | 1993-11-25 |
CA2136208C (en) | 1999-08-10 |
ES2132239T3 (en) | 1999-08-16 |
CA2276548A1 (en) | 1993-11-25 |
WO1993023540A3 (en) | 1994-01-20 |
JPH08500730A (en) | 1996-01-30 |
US5439807A (en) | 1995-08-08 |
GR3030419T3 (en) | 1999-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2276548C (en) | Improved methods for the preparation of endotoxin-binding proteins | |
US5284933A (en) | Affinity peptides | |
Hardie et al. | In vitro activation of Escherichia coli prohaemolysin to the mature membrane‐targeted toxin requires HlyC and a low molecular‐weight cytosolic polypeptide | |
EP0305500B1 (en) | Process for the purification of recombinant polypeptides | |
CA2249180C (en) | Methods for recombinant microbial production of bpi-fusion proteins and bpi-derived peptides | |
AU686996B2 (en) | Serum-human albumin, preparation and utilization | |
KR100203512B1 (en) | Recombinant core-streptavidin | |
US6242219B1 (en) | Methods for recombinant peptide production | |
KR0159107B1 (en) | Protein with urate oxidase activity, recombinant gene coding therefor, expression vector, micro-organisms and transformed cell | |
RU2232772C2 (en) | Modified human granulocyte colony-stimulating factor and method for its preparing, dna, expressing vector | |
JP2525023B2 (en) | Purification of recombinant interleukin-1 | |
EP0567503B1 (en) | Pasteurella haemolytica glycoprotease gene | |
Uhlén et al. | The gene for staphylococcal protein A | |
Burton et al. | Expression in Escherichia coli: purification and properties of the yeast general transcription factor TFIID | |
Kool et al. | Bacteriocinogenic Clo DF13 minicells of Escherichia coli synthesize a protein that accounts for immunity to bacteriocin Clo DF13: purification and characterization of the immunity protein | |
JP3840674B2 (en) | Purification method of human serum albumin derived from genetic manipulation | |
JPH04502260A (en) | N-acetylmuramidase M1 | |
CA2198361A1 (en) | Intracellular delivery of chemical agents to a specific cell type | |
Ogata et al. | Growth stimulation of human melanocytes: identification and characterization of melanoma-derived melanocyte growth factor (M-McGF) | |
JPH05168478A (en) | Making of recombinant iga-protease and method of decomposing fused protein obtained by art of recombinant iga- protease, recombinant dna, recombinant vector, cell and gene. | |
JP4016999B2 (en) | Purification method of human serum albumin derived from genetic manipulation | |
Fields et al. | Failure to detect binding of LcrH to the V antigen of Yersinia pestis | |
CN109111489B (en) | Method for enriching glycoprotein based on animal galectin-3 carbohydrate recognition structural domain | |
US20020006638A1 (en) | Methods for recombinant microbial production of fusion proteins and BPI-derived peptides | |
KR0141315B1 (en) | Novel process for preparing human thymosin alphai |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |